A Multicenter, Randomized, Placebo-controlled, Parallel Group, Double Blind, Dose-finding Phase II Trial to Study the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of the Oral Partial Adenosine A1 Receptor Agonist Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure and Preserved Ejection Fraction
Phase: PHASE2
Conditions: Heart Failure
Sponsor: Bayer

 
Document Type: Study Protocol 
Official Title: 
A multicenter, randomized, placebo-controlled, parallel group, 
double blind, dose-finding Phase II trial to study the efficacy, 
safety, pharmacokinetics and pharmacodynamic effects of the 
oral partial adenosine A1 receptor agonist neladenoson bialanate 
over 20 weeks in patients with chronic heart failure and preserved 
ejection fraction 
NCT Number: 
NCT03098979 
Document Date: 
14 Feb 2017 
 

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 1 of 85
1.
Title page
A multicenter, randomized, placebo-controlled, parallel group, double blind, dose-finding 
Phase II trial to study the efficacy, safety, pharmacokinetics and pharmacodynamic effects of 
the oral partial adenosine A1 receptor agonist neladenoson bialanate over 20 weeks in 
patients with chronic heart failure and preserved ejection fraction
Short title:
PANACHE
Test drug:
neladenoson bialanate / BAY 1067197
Study purpose:
dose finding
Clinical study phase:
IIb
Date:
14 FEB 2017
Registration:
EudraCT no.: 2016-004062-26 Version no.:
1.0
Sponsor’s study no.:
BAY 1067197 / 17582
Sponsor:
Non-US: Bayer AG, D-51368 Leverkusen, Germany
US territory: Bayer HealthCare Pharmaceuticals Inc., 100 Bayer 
Boulevard, P.O. Box 915, Whippany NJ 07981-0915, USA
Sponsor’s medical 
expert:
Bayer AG
Aprather Weg 18 a, building 402
42113 Wuppertal, Germany
Phone: 
Email: 
The study will be conducted in compliance with the protocol, ICH-GCP and any applicable 
regulatory requirements.
Confidential
The information provided in this document is strictly confidential and is intended solely for 
the guidance of the clinical investigation. Reproduction or disclosure of this 
document - whether in part or in full - to parties not associated with the clinical investigation, 
or its use for any other purpose, without the prior written consent of the sponsor is not 
permitted.
Throughout this document, symbols indicating proprietary names (, TM) may not be displayed. Hence, the 
appearance of product names without these symbols does not imply that these names are not protected.
PPD
PPD
PPD
PPD

14FEB2017 
Clinical Study Protocol 
No. BAY 1067197 / 17582 
Version: 1.0 
Signature of the sponsor's medically responsible person 
Page: 2 of 85 
The signatory agrees to the content of the final clinical study protocol as presented. 
Name: 
 
Role: 
Global Clinical Leader 
Signature: 
PPD
PPD

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 3 of 85
Signature of principal investigator
The signatory agrees to the content of the final clinical study protocol as presented.
Name:
Affiliation:
Date:
Signature:
Signed copies of this signature page are stored in the sponsor’s study file and in the respective 
center’s investigator site file.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 4 of 85
2.
Synopsis
Title
A multicenter, randomized, placebo-controlled, parallel group, double blind, 
dose-finding Phase II trial to study the efficacy, safety, pharmacokinetics and 
pharmacodynamic effects of the oral partial adenosine A1 receptor agonist 
neladenoson bialanate over 20 weeks in patients with chronic heart failure and 
preserved ejection fraction
Short title
PANACHE
Clinical study phase
IIb
Study objective(s)
The objective of the study is to find the optimal dose of neladenoson bialanate 
for the Phase III trial by detecting and characterizing a significant dose-
response relationship in the primary efficacy endpoint, absolute change from 
baseline in 6-minute walking distance (6MWD) at 20 weeks, in patients with 
chronic heart failure with preserved ejection fraction (HFpEF), and by 
characterizing the safety, tolerability and pharmacodynamic effects of the 
compound when given in addition to appropriate therapy for specific co-
morbidities. 
An exploratory objective is to further assess pharmacokinetic parameters and 
blood and urine biomarkers.
Test drug(s)
Name of active ingredient neladenoson bialanate
Dose(s)
5 mg, 10 mg, 20 mg, 30 mg, and 40 mg once daily
Route of administration
Oral
Duration of treatment
20 weeks
Reference drug(s)
Name of active ingredient Placebo
Dose(s)
Not applicable
Route of administration
Oral
Duration of treatment
20 weeks
Background treatment
Appropriate therapy for specific co-morbidities given concomitantly with the 
test drug / placebo
Indication
Chronic heart failure (NYHA II-IV) with preserved ejection fraction 
Diagnosis and main criteria 
for inclusion 
1.
Men or women aged 45 years and older
2.
Diagnosis of chronic heart failure (CHF), NYHA class II-IV (without 
evidence of a non-cardiac explanation for dyspnea), LVEF ≥ 45% 
assessed by any imaging modality (e.g. echocardiography, cardiac 
magnetic resonance, cine levocardiography) within the previous 6 
months with no significant change in clinical status suggesting potential 
for deterioration in ejection fraction. 
3.
In the 6 months prior to run-in: 
a) Requirement of treatment with a diuretic
AND
b) Elevated natriuretic peptides, defined as one of:
o BNP ≥ 75 pg/mL or NT-proBNP ≥ 300 pg/mL (sinus rhythm)
o BNP ≥ 200 pg/mL or NT-proBNP ≥ 900 pg/mL (atrial fibrillation)
AND

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 5 of 85
c) At least one of the following:
o LA enlargement (LA diameter ≥ 3.9 cm, LA volume ≥ 55 mL, 
LAVI ≥ 29 mL/m2, or LAA ≥ 20 cm2) (assessed by local imaging)
o LV hypertrophy (septal or posterior wall thickness ≥ 1.1 cm) (local 
imaging)
o Elevated filling pressures (invasive assessment) at rest (PAWP ≥ 20 
mmHg or LVEDP ≥ 15 mmHg) or with exercise (PAWP ≥ 25 
mmHg) (historical records)
4.
6MWD ≥ 100 m and ≤ 550 m at Visit 2 (baseline)
5.
Written informed consent signed before any study-specific procedure
Diagnosis and main criteria 
for exclusion
1.
Acute decompensated heart failure (defined as acute exacerbation of HF 
that may require IV therapy with diuretics, vasodilators or inotropic drugs 
and / or mechanical support) within the past 4 weeks
2.
Initiation or dose modification of cardiovascular pharmacological therapy 
within the past 2 weeks (dose modification of pre-existing diuretic /
anticoagulant medication is allowed based on patient-specific needs)
3.
Inability to exercise: wheelchair / scooter / walker dependent; dependent 
on supplemental oxygen
4.
HF is not the primary factor limiting activity as indicated by the patient 
affirming #1, #2 or #3 of the following questionnaire:
My ability to be active is most limited by:
#1 - Joint, foot, leg, hip or back pain
#2 - Unsteadiness or dizziness impairing daily mobility
#3 - Lifestyle, weather, or I just don’t like to be active
5.
Previous diagnosis of HFrEF (LVEF < 40%)
6.
Known clinically significant persistent coronary ischemia (based on 
medical history, a preexisting or a recent clinical stress test)
7.
Occurrence of any of the following within the previous 3 months:
o Clinically evident myocardial infarction
o Hospitalization for unstable angina
o Stroke or transient ischemic attack
o Coronary artery bypass graft (CABG) 
o Percutaneous coronary intervention (PCI)
o Implantation of a cardiac resynchronization therapy device (CRTD)
o Major surgery (that could interfere with patients’ ability to exercise) 
8.
PCI, CABG or implantation of a CRTD planned between randomization 
and end of study
9.
Sustained * systolic blood pressure ≤ 90 mmHg and / or signs and 
symptoms of hypotension prior to randomization
10. Sustained * systolic blood pressure ≥ 160 mmHg prior to randomization
11. Sustained * bradycardia with heart rate < 50 beats/minute or tachycardia 
with heart rate > 100 beats/minute prior to randomization
* At two consecutive visits

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 6 of 85
12. Known clinically relevant ventricular arrhythmias (sustained ventricular 
tachycardia, ventricular flutter or fibrillation) within 3 months prior to 
randomization based on either medical history or device generated data (if 
applicable)
13. Clinically relevant permanent or intermittent AV-block > grade II in 
patients without a permanent pacemaker or ICD / CRTD
14. Severe uncorrected valvular heart disease
15. Listing for heart transplantation and / or anticipated implantation of a 
ventricular assist device
16. Severe pulmonary disease with any of the following:
o Requirement of continuous (home) oxygen or 
o History of chronic obstructive pulmonary disease ≥ GOLD III 
o Use of systemic corticosteroids
17. Asthma bronchiale with any of the following:
o Symptoms not well-controlled within the past 6 months or 
o Ever intubated or in an intensive care unit for asthma
18. Anemia with hemoglobin < 10 g/dL within 3 months prior to 
randomization. If several values are available the latest result should be 
used. 
19. Body mass index (BMI) > 45 kg/m2 at randomization
20. Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2
calculated by Modification of Diet in Renal Disease (MDRD) formula 
within 3 months prior to randomization. If several values are available the 
latest result should be used.
21. Hepatic insufficiency classified as Child-Pugh B or C, or any of the 
following: 
o Primary biliary cirrhosis (PBC)
o Primary sclerosing cholangitis
o PBC-autoimmune hepatitis overlap syndrome
22. Concomitant use of any of the following therapy that cannot be 
discontinued:
o Moderate or strong CYP3A4 inhibitors (Of note: grapefruit is a 
strong CYP3A4 inhibitor)
o CYP3A4 inducers
o Strong CYP2C8 inhibitors (Of note: clopidogrel is a strong CYP2C8 
inhibitor)
o Theophylline
o Drugs having significant pre-systemic clearance via UGT1A1 in the 
intestine
Respective substances must be stopped at least 7 days before 
randomization.
23. Women of childbearing potential (women are considered of childbearing 
potential if they are not surgically sterile or postmenopausal, defined as 
amenorrhea for > 12 months) 
24. Known current heavy alcohol consumption or the use of illicit drugs that 
may interfere with the patient’s safety and / or compliance
25. Previous (within 30 days or 5 half-lives of the investigational drug, 
whichever is longer) or concomitant participation in another clinical study 
with investigational medicinal product(s) or device(s)
26. Previous assignment to treatment during this study

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 7 of 85
27. Any condition or therapy, which would make the patient unsuitable for 
the study, or life expectancy less than 12 months (e.g. active malignancy) 
28. Close affiliation with the investigational site; e.g. a close relative of the 
investigator, dependent person (e.g. employee or student of the 
investigational site)
29. Known allergies, intolerance or hypersensitivities to the study treatment 
(active substance or excipients), adhesives or hydrogel
Study design
Multicenter, randomized, placebo-controlled, parallel group, double blind, 
dose-finding
Methodology
The study will comprise a 1-week run-in period, 20-week treatment period, and 
a 6-week follow-up period (27 weeks total). 
Patients will have site visits at Weeks -1, 0 (baseline), 4, 8, 12, 20 (end of 
treatment visit) and 24 (safety follow-up visit). In addition, 2 phone calls at 
Weeks 2 and 26 will be made to assess patients’ safety, and one additional 
phone call – to remind the patients of AVIVO self-application at Week 19.
6MWD test (including Borg CR 10 Scale) will be done during the run-in, to 
familiarize patients with the test, and at baseline, Week 8 and end of 
treatment / premature discontinuation visits. Safety will be monitored 
throughout the study. PK samples will be taken from all patients at dedicated 
time points. Biomarkers reflecting the pharmacodynamic activity of the drug 
will be examined, as well as candidate biomarkers that may predict drug 
response.
Type of control
Placebo control
Data Monitoring Committee Yes
Number of patients
Approximately 288 patients are planned to be randomized. 
Primary variable
Absolute change from baseline in 6MWD after 20 weeks of treatment
Time point / frame of 
measurement for
primary variable
After 20 weeks of treatment
Plan for statistical analysis
The primary efficacy analysis will be performed on the primary efficacy 
variable in patients belonging to the per-protocol set using a type I error of 5%.
For the assessment of a dose-response relationship in the absolute change in 
6MWD, the MCP-Mod method, combining multiple comparison procedures 
(MCP) with modeling techniques under model uncertainty, will be used. 
A set with 5 candidate dose-response models has been specified. For the 
detection of a dose-response signal, each of the dose-response models in the 
candidate set will be tested at the corresponding type I error level, using a one-
sided multiple contrast test based on pre-specified contrast coefficients. If a 
dose-response signal is established, a dose-response model will be fitted to the 
data and target dose(s) of interest will be estimated based on the estimated 
dose-response model.
Other efficacy variables will be analyzed analogously to the primary variable or 
descriptively.  

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 8 of 85
Table of contents
1.
Title page............................................................................................................................ 1
2.
Synopsis.............................................................................................................................. 4
Table of contents....................................................................................................................... 8
Table of tables......................................................................................................................... 11
Table of figures....................................................................................................................... 11
List of abbreviations............................................................................................................... 12
3.
Introduction..................................................................................................................... 16
3.1
Background.................................................................................................................... 16
3.2
Partial adenosine A1 receptor agonism in heart failure................................................. 18
3.3
Neladenoson bialanate ................................................................................................... 20
3.4
Rationale of the study .................................................................................................... 21
4.
Study objectives............................................................................................................... 21
5.
Study design..................................................................................................................... 22
5.1
Design overview ............................................................................................................ 22
5.2
Primary variable............................................................................................................. 23
5.3
Justification of the design .............................................................................................. 23
5.4
End of study................................................................................................................... 23
6.
Study population ............................................................................................................. 23
6.1
Inclusion criteria ............................................................................................................ 23
6.2
Exclusion criteria ........................................................................................................... 24
6.3
Justification of selection criteria.................................................................................... 26
6.4
Withdrawal of patients from study ................................................................................ 26
Withdrawal ................................................................................................................. 26
6.4.1
Replacement ............................................................................................................... 28
6.4.2
6.5
Patient identification...................................................................................................... 28
7.
Treatments....................................................................................................................... 28
7.1
Treatments to be administered....................................................................................... 28
7.2
Identity of study treatment............................................................................................. 29
7.3
Treatment assignment.................................................................................................... 30
7.4
Dosage and administration............................................................................................. 30
7.5
Blinding ......................................................................................................................... 30
7.6
Drug logistics and accountability................................................................................... 31
7.7
Treatment compliance.................................................................................................... 31
8.
Non-study therapy........................................................................................................... 32
8.1
Prior and concomitant therapy....................................................................................... 32
Prohibited concomitant medication............................................................................ 32
8.1.1
Permitted therapy........................................................................................................ 32
8.1.2
8.2
Post-study therapy.......................................................................................................... 32

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 9 of 85
9.
Procedures and variables ............................................................................................... 33
9.1
Tabular schedule of evaluations .................................................................................... 33
9.2
Visit description............................................................................................................. 36
Visit 1 (Week -1, run-in) ............................................................................................ 36
9.2.1
Visit 2 (Week 0, baseline) .......................................................................................... 36
9.2.2
Visit 3 (Week 2, phone call)....................................................................................... 37
9.2.3
Visit 4 (Week 4) ......................................................................................................... 37
9.2.4
Visit 5 (Week 8) ......................................................................................................... 38
9.2.5
Visit 6 (Week 12) ....................................................................................................... 38
9.2.6
Reminder phone call at Week 19................................................................................ 39
9.2.7
Visit 7 (Week 20, EOT or premature discontinuation) .............................................. 39
9.2.8
Visit 8 (Week 24, safety follow-up)........................................................................... 40
9.2.9
Visit 9 (Week 26, phone call)..................................................................................... 41
9.2.10
Unscheduled Visit ...................................................................................................... 41
9.2.11
9.3
Population characteristics .............................................................................................. 41
Demographic and vital signs ...................................................................................... 41
9.3.1
Medical history........................................................................................................... 42
9.3.2
Other baseline characteristics..................................................................................... 42
9.3.3
9.4
Efficacy.......................................................................................................................... 42
6MWD test ................................................................................................................. 42
9.4.1
Borg CR 10 Scale ....................................................................................................... 42
9.4.2
Echocardiography....................................................................................................... 43
9.4.3
Biomarker investigations............................................................................................ 44
9.4.4
Clinical efficacy variables .......................................................................................... 45
9.4.5
9.4.5.1
Clinical outcome events .......................................................................................... 45
9.4.5.2
NYHA class assessment.......................................................................................... 45
Patient-reported outcomes.......................................................................................... 46
9.4.6
9.4.6.1
KCCQ...................................................................................................................... 46
9.4.6.2
EQ-5D-5L................................................................................................................ 47
9.5
Pharmacokinetics / pharmacodynamics ......................................................................... 47
9.6
Safety ............................................................................................................................. 48
Adverse events............................................................................................................ 48
9.6.1
9.6.1.1
Definitions............................................................................................................... 48
9.6.1.2
Classifications for adverse event assessment.......................................................... 49
9.6.1.2.1
Seriousness........................................................................................................... 49
9.6.1.2.2
Intensity................................................................................................................ 49
9.6.1.2.3
Causal relationship............................................................................................... 49
9.6.1.2.4
Action taken with study treatment ....................................................................... 50
9.6.1.2.5
Other specific treatment(s) of adverse events...................................................... 51
9.6.1.2.6
Outcome............................................................................................................... 51
9.6.1.3
Assessments and documentation of adverse events ................................................ 51
9.6.1.4
Reporting of serious adverse events........................................................................ 51
9.6.1.5
Expected adverse events.......................................................................................... 52
9.6.1.6
Adverse events of special interest........................................................................... 53
Pregnancies................................................................................................................. 53
9.6.2

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 10 of 85
Further safety.............................................................................................................. 53
9.6.3
9.6.3.1
Laboratory evaluations............................................................................................ 53
9.6.3.2
Physical examination............................................................................................... 54
9.6.3.3
12-lead ECG............................................................................................................ 54
9.6.3.4
Blood pressure and heart rate.................................................................................. 54
9.6.3.5
AVIVO monitoring ................................................................................................. 54
9.6.3.6
Liver function monitoring....................................................................................... 55
9.7
Other procedures and variables...................................................................................... 55
9.8
Appropriateness of procedures / measurements............................................................. 55
10. Statistical methods and determination of sample size ................................................. 56
10.1
General considerations................................................................................................... 56
10.2
Analysis sets .................................................................................................................. 56
10.3
Variables and planned statistical analyses..................................................................... 57
Variables..................................................................................................................... 57
10.3.1
10.3.1.1
Primary efficacy variable ........................................................................................ 57
10.3.1.2
Secondary efficacy variables................................................................................... 57
10.3.1.3
Other exploratory variables..................................................................................... 57
10.3.1.4
Safety variables ....................................................................................................... 58
Statistical and analytical plans.................................................................................... 58
10.3.2
10.3.2.1
Subgroups................................................................................................................ 58
10.3.2.2
Analysis of the primary efficacy variable ............................................................... 59
10.3.2.3
Analysis of the secondary efficacy variables .......................................................... 62
10.3.2.4
Analysis of the safety variables............................................................................... 63
10.3.2.5
Pharmacokinetic analyses ....................................................................................... 63
10.3.2.6
Biomarker analyses ................................................................................................. 64
Missing data, censoring due to death, and drop outs.................................................. 64
10.3.3
10.4
Determination of sample size......................................................................................... 66
10.5
Planned interim analyses ............................................................................................... 67
11. Data handling and quality assurance............................................................................ 67
11.1
Data recording................................................................................................................ 67
11.2
Monitoring ..................................................................................................................... 68
11.3
Data processing.............................................................................................................. 69
11.4
Missing data................................................................................................................... 69
11.5
Audit and inspection ...................................................................................................... 69
11.6
Archiving ....................................................................................................................... 70
12. Premature termination of the study .............................................................................. 70
13. Ethical and legal aspects................................................................................................. 71
13.1
Investigator(s) and other study personnel...................................................................... 71
13.2
Funding and financial disclosure ................................................................................... 72
13.3
Ethical and legal conduct of the study........................................................................... 72
13.4
Patient information and consent .................................................................................... 73
13.5
Publication policy and use of data ................................................................................. 74
13.6
Compensation for health damage of patients / insurance............................................... 74
13.7
Confidentiality ............................................................................................................... 75

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 11 of 85
14. Reference list.................................................................................................................... 75
15. Protocol amendments...................................................................................................... 81
16. Appendices....................................................................................................................... 82
16.1
Calculating glomerular filtration rate ............................................................................ 82
16.2
Calculating the Child-Pugh score .................................................................................. 82
16.3
6-minute walking distance (6MWD) test....................................................................... 83
16.4
Borg CR 10 Scale and test instructions ......................................................................... 85
Table of tables
Table 7—1: Identity of neladenoson bialanate (BAY 1067197) ............................................. 29
Table 7—2: Identity of placebo ............................................................................................... 29
Table 7—3: Assignment of tablets to dose groups .................................................................. 30
Table 9—1: Schedule of evaluations ....................................................................................... 34
Table 9—2: Sample types used for biomarker investigations.................................................. 45
Table 9—3: Liver function monitoring.................................................................................... 55
Table 10—1: Dose-response shapes used in the candidate set ................................................ 60
Table 10—2: Power for multiple contrast test for set of different alternatives........................ 66
Table 16–1: Grading of severity of liver disease ..................................................................... 82
Table 16–2: Classification using the added score from Table 16–1 ........................................ 82
Table of figures
Figure 5—1: Study design overview........................................................................................ 22
Figure 9—1: KCCQ Scores...................................................................................................... 47
Figure 10—1: Dose-response shapes used in the candidate set............................................... 61

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 12 of 85
List of abbreviations
6MWD
6-minute walking distance
A1R
A1 receptor
ACE
angiotensin-converting enzyme
ACEi
ACE inhibitor
ADHF
acute decompensated heart failure
ADP
adenosine diphosphate
AE(s)
adverse event(s)
AF
atrial fibrillation
ALT
alanine aminotransferase
AP
alkaline phosphatase
ARB(s)
angiotensin receptor blocker(s)
ARNI(s)
angiotensin receptor-neprilysin inhibitor(s)
AST
aspartate aminotransferase
ASWT
anteroseptal wall thickness
ATP
adenosine triphosphate
AUC
area under the time-concentration curve
AV
atrioventricular
BCRP
breast cancer resistance protein
BM
biomarker
BMI
body mass index
BNP
b-type natriuretic peptide
BSA
body surface area
%CV
percent coefficient of variation
CABG
coronary artery bypass graft
cAMP
cyclic adenosine monophosphate
CAD
coronary artery disease
CE mark
European Conformity mark (Conformité Européenne)
CEC
Clinical Events Committee
CHF
chronic heart failure
CI
cardiac index
CK
creatine kinase
CKD
chronic kidney disease
Cmax
maximum drug concentration in plasma
CNS
central nervous system
CO
cardiac output
CRF
case report form
CRO
contract research organization
CRTD
cardiac resynchronization therapy device
CV
cardiovascular
CYP
cytochrome P450
DBP
diastolic blood pressure
DMC
Data Monitoring Committee

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 13 of 85
e.g.
for example (exempli gratia)
EC(s)
Ethics Committee(s)
ECG
electrocardiogram
eCRF
electronic CRF
EDC
electronic data capture
EF
ejection fraction
eGFR
estimated glomerular filtration rate
EMA
European Medicines Agency
EOT
end of treatment
EQ-5D-5L
EuroQol Group 5-dimensional, 5-level questionnaire
ESC
European Society of Cardiology
EU
European Union
EWDT
E-wave deceleration time
FAS
full analysis set
FDA
(US) Food and Drug Administration 
FFA
free fatty acids
FU
follow up
FWER
family-wise error rate
Gal-3
galectin-3
GCP
Good Clinical Practice
GDF-15
growth differentiation factor 15
GFR
glomerular filtration rate
GGT
gamma glutamyl transpeptidase
GMP
Good Manufacturing Practice
GOLD
Global Initiative for Chronic Obstructive Lung Disease
GPV
global pharmacovigilance
HbA1c
hemoglobin A1c
HCl
hydrochloride
HDL
high-density lipoprotein
HF
heart failure
HFpEF
heart failure with preserved ejection fraction
HFrEF
heart failure with reduced ejection fraction
HHF
hospitalized heart failure
HIV
human immunodeficiency virus
HR
heart rate
hs-TNT
high sensitivity troponin T
i.e.
that is (id est)
IB
investigator's brochure
ICD
implantable cardioverter defibrillator
ICF
informed consent form

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 14 of 85
ICH
International Conference on Harmonization
IDMS
Isotope dilution mass spectroscopy
IEC
Independent Ethics Committee
INR
international normalized ratio
IRB
Institutional Review Board
ITT
intent-to-treat
IV
intravenous(ly) 
IVSD
interventricular septum diameter  
IxRS
interactive web / voice response system
KCCQ
Kansas City cardiomyopathy questionnaire
LA
left atrial
LAA
left atrial appendage
LAV
LA volume
LAVI
LA volume index
LDH
lactate dehydrogenase 
LDL
low-density lipoprotein
LV
left ventricular
LVEDP
LV end-diastolic pressure
LVEDV
LV end-diastolic volume
LVEDVI
LVEDV index 
LVEF
left ventricular ejection fraction
LVESV
left ventricular end-systolic volume
LVESVI
LVESV index
MAP
mean arterial pressure
MCH
mean corpuscular hemoglobin
MCHC
MCH concentration
MCP
multiple comparison procedures
MCV
mean corpuscular volume
MDRD
modification of diet in renal disease
MedDRA
Medical Dictionary for Regulatory Activities
mL
milliliter
mmHg
millimeter of mercury 
MR-proANP
mid-regional pro-atrial natriuretic peptide
NGAL
neutrophil gelatinase-associated lipocalin
NONMEM
non-linear mixed effect modeling
NT-proBNP
N-terminal pro-hormone b-type natriuretic peptide
NYHA
New York Heart Association
OPN
osteopontin 
PASP
pulmonary artery systolic pressure
PAWP
pulmonary artery wedge pressure

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 15 of 85
PBC
primary biliary cirrhosis
PCI
percutaneous coronary intervention
PD
pharmacodynamic
PDV
premature discontinuation visit
Pes
end-systolic pressure
pg
picogram
PK
pharmacokinetic
PKS
PK analysis set
PP
pulse pressure
PPS
per-protocol set
PRO(s)
patient-reported outcome(s)
PTT
partial thromboplastin time
PWT
posterior wall thickness
QC
quality control
QoL
quality of life
QTcB
QT interval frequency-corrected according to Bazett’s formula
RV
right ventricular
SAC
systemic arterial compliance
SAE(s)
serious adverse event(s)
SAF
safety analysis set
SAP
statistical analysis plan
SBP
systolic blood pressure
SERCA
sarcoplasmic reticulum calcium adenoside triphosphatase
sST2
soluble suppression of tumorigenicity-2
SUSAR(s)
suspected unexpected serious adverse reaction(s)
SV
stroke volume
SVI
SV index
SVT(s)
supraventricular tachycardia(s)
TAPSE
tricuspid annular plane systolic excursion
TD
tissue Doppler
TIMP-4
tissue inhibitor of metalloproteinase-4
TPR
total peripheral resistance
UACR
urine albumin-to-creatinine ratio
UGT1A1
uridine diphosphate glucuronosyltransferase 1A1
ULN
upper limit of normal
US(A)
United States (of America)
VAS
visual analogue scale
WCHF
worsening chronic heart failure

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 16 of 85
3.
Introduction
3.1
Background
Chronic heart failure (CHF) is a major public health problem characterized by significant 
mortality, frequent hospitalizations, and poor quality of life, with an overall prevalence that is 
increasing throughout the world. The European Society of Cardiology (ESC) represents 
countries with a population of > 900 million, and there are at least 15 million patients with
heart failure (HF) in those 51 countries (1). An estimated 5.7 million patients have HF in the 
United States (US) with increasing prevalence, and the incidence approaches 10 per 1000 
population after 65 years of age; the lifetime risk for developing HF is one in five for men and 
women (2). In developed countries 1-2% of the adult population has HF, with the prevalence 
rising to ≥ 10% among persons 80 years of age or older (3). HF carries a prognosis 
comparable to many forms of cancer with a 5-year survival rate of approximately 50% (4), 
which exceeds that of many cancers (5).
In the recent years, HF has been shown to occur in patients with near normal or preserved 
systolic function; a condition termed as “heart failure with preserved ejection fraction” 
(HFpEF). Currently, HFpEF accounts for approximately half of HF cases, and the prevalence 
of HFpEF, as well as its relative proportion compared with heart failure with reduced ejection 
fraction (HFrEF), has been increasing in recent years (6-8). Compared with HFrEF, patients 
with HFpEF are older, more often women and more commonly have a history of hypertension 
and atrial fibrillation (AF), while a history of myocardial infarction is less common (9).
HF is resulting in more than 1 million admissions per year as a primary diagnosis both in the 
US and Europe, representing 1% to 2% of all hospitalizations (2), thus being one of the 
leading causes of hospitalization. The relative proportion of HFpEF has increased to more 
than 45% of all HF hospitalizations (10) and hospitalization related to HF is the single most 
common cause of hospitalization in the HFpEF population, despite multiple significant 
comorbidities. Frequent hospitalizations, along with other direct and indirect costs, also place 
an enormous financial burden on healthcare systems; more is spent annually in the US for the 
treatment of HF by Medicare than on any other Medicare-covered condition (11).
Most patients with hospitalized heart failure (HHF) suffer from worsening of established HF 
(6). The prognosis of patients admitted to the hospital for HF is particularly unfavorable, as 
recurrent HF hospitalizations are representing an important marker of disease progression and 
an important indicator of poor outcomes (12, 13): within 60 to 90 days after discharge, 
patients with HHF continue to have a mortality and readmission rate approaching 15% and 
30%, respectively, with the most common cause of death being progressive HF (14). Overall, 
patients with HFpEF have similar rates of post-discharge mortality compared with those with 
HFrEF, but the mode of death may differ (6). In addition, these patients have moderate to 
severe signs and symptoms throughout their course.
Exercise intolerance, with symptoms of dyspnea and fatigue with exertion and measured 
objectively with a variety of exercise test modalities, is the primary manifestation of chronic 
HFpEF, even when patients are stable and well-compensated (15). Exercise intolerance is 
associated with reduced health-related quality of life.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 17 of 85
Mechanisms implicated in HFpEF include abnormal relaxation and reduced left ventricular 
compliance with resultant increase in ventricular filling pressures, increased vascular 
stiffness, abnormal systolic function despite preserved ejection fraction, interstitial fibrosis, 
coronary disease and microvascular dysfunction (7, 16-20). Furthermore, it is well established 
that energy deficiency contributes to the syndrome of HF (21, 22), and it has been shown that 
altered myocardial energetics underlie diastolic function abnormalities in HFpEF, especially 
under exercise conditions (23).
In addition, HFpEF is strongly influenced by aging, a systemic process affecting all organ 
systems. The impact of multiple comorbidities typical of older HFpEF patients contributes to 
the phenotypic heterogeneity and multifactorial pathophysiology of the disease (24). Owing to
this complexity, among other things, currently no consensus diagnostic approach to HFpEF 
exists in the professional community. The recommendations essentially involve establishing 
that the HF clinical syndrome is present in the absence of other etiologies for dyspnea and 
volume overload. Therefore it seems reasonable to use a multitiered approach with the goal of 
identifying that there is a significant cardiovascular limitation driving the symptoms of 
dyspnea and functional intolerance, integrating the clinical presentation, the documentation of 
a preserved ejection fraction and the elevation of natriuretic peptide levels to support the 
diagnosis (25). 
In contrast to the many studies that have shown a benefit of pharmacologic therapies in 
HFrEF, outcome trials including ACE inhibitors, mineralocorticoid receptor antagonists and 
ß-blockers have failed to show a benefit on the natural history of HFpEF (26-30). Almost no 
subgroups have revealed any favorable signals either, save for the possibility of 
mineralocorticoid antagonist effects in HFpEF patients enrolled in the Americas in the 
Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist 
(TOPCAT) trial (31). In addition, there are several retrospective analyses which have shown 
that standard therapies do not work. 
Pooled analysis of prospective HFpEF studies demonstrates that coronary heart disease 
(CAD) is common in HFpEF, with an estimated prevalence of approximately 45% (32).
Slowing an elevated heart rate can prolong LV filling time in an abnormally stiff ventricle and 
also prolong coronary perfusion. However, a recent post-hoc analysis from the CHARISMA-
trial in patients with CAD showed that β-blocker use was not associated with lower 
cardiovascular events in those without previous myocardial infarction (33).
Besides, limited heart rate increase (chronotropic incompetence) significantly contributes to 
low cardiac output augmentation with exercise in patients with HFpEF (34). There is a high 
prevalence of chronotropic incompetence in patients with HFpEF reported by clinical trials, 
which may already be a contributing factor to symptoms because of limited increase in 
cardiac output with exertion (23, 35). In these circumstances, further blunting heart rate by the 
use of ß-blockers seems unlikely to benefit HFpEF patients, as this could lead to worsening 
exercise capacity. 
Accordingly, the evidence base for clinical efficacy for the use of ß-blocker therapy in HFpEF 
is inconclusive, and the results of ß-blocker trials in HFpEF are neutral. Therefore, current 
guidelines do not recommend the use of ß-blockers solely for HFpEF, unless they are used to 

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 18 of 85
optimize treatment of comorbidity, such as controlling ventricular rate in atrial fibrillation or 
treating CAD (36-40). 
In summary, there is no evidence-based therapy specific for HFpEF, but only general 
treatment recommendations exist, including the use of diuretics, caloric restriction diet, 
exercise training, and anticoagulation in the presence of atrial fibrillation (41). These are 
presumed to be beneficial to the vast majority of HFpEF patients because they address the 
presentation phenotype of lung congestion and the predisposition phenotype of 
overweight / obesity present in > 80% of HFpEF patients (42), as well as the common 
comorbid condition of arrhythmias like atrial fibrillation (43). 
Thus, a substantial unmet medical need exists for clinical trials investigating therapeutic 
options targeting mechanisms involved in HFpEF (44-47). As evidence has suggested a 
crucial role of cardiac energetic impairment in the pathophysiology of HFpEF, cardiac 
energetics and altering cardiac substrate use represent promising targets for HFpEF therapy. 
Apart from the fact that the treatment paradigm for patients with HFrEF, which centers on 
systemic blockade of the maladaptive neurohumoral response, does not seem to be working in 
the same way in HFpEF, the repeated stepwise addition of hemodynamically active 
medications raises tolerability and safety concerns (e.g. hypotension and bradycardia) (48), 
and hemodynamic compromise represents a frequent reason for failed HF drug development 
(49).
Therefore, addressing the failing heart directly might be a new option for the development of 
the next generation of hemodynamically silent HF drugs. In this context, neladenoson 
bialanate holds promise as a potentially hemodynamically neutral therapy for HF that could 
simultaneously improve cardiomyocyte energetics, calcium homeostasis, cardiac structure and 
function, and long-term clinical outcomes when added to background therapies. If positive, 
this study would provide a novel treatment strategy for this large group of patients with 
currently very limited treatment options.
3.2
Partial adenosine A1 receptor agonism in heart failure
The failing heart is characterized by abnormal mitochondrial structure and function including 
hyperplasia and reduced organelle size, poor organelle respiration, reduced mitochondrial 
membrane potential, opening of membrane permeability pores, and reduced rates of adenosine 
triphosphate (ATP) synthesis and thereby reduced energy supply in cardiomyocytes in HFpEF 
and HFrEF (16, 50-55). Additionally Ca2+ handling is disturbed and SERCA2a protein levels 
are decreased in HF (56), which changes the contraction / relaxation coupling in 
cardiomyocytes and leads to an intracellular calcium overload in the heart. Furthermore, 
systemic metabolic impairments in the skeletal muscle are increasingly recognized as 
contributing both to symptoms (muscle weakness, exercise limitation) and disease 
progression in HF (57). Preclinical studies have demonstrated that myocardial energy 
metabolism and utilization as well as calcium homeostasis are improved by the partial 
adenosine A1 receptor agonist capadenoson (50, 58). In the heart failure standard dog model, 
treatment with this drug showed fast improvement of cardiac energetics (ATP synthesis) via 
mitochondrial effects. Capadenoson further improved SERCA2a activity, leading to decreased 
intracellular calcium overload (50).

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 19 of 85
The high prevalence of CAD in patients with HFpEF is associated with greater deterioration 
in ventricular function and increased mortality (59, 60) based mainly on ischemia driven 
injury of cardiac tissue. The primary physiological undertaking of adenosine is to preclude 
tissue injury and promote repair in response to stress mainly through adenosine A1 receptors 
(A1R) activation. Preclinical data showed cardioprotection from ischemia-induced injury by 
preconditioning and improvement of endothelial function in animal models with partial A1R
agonists including capadenoson (50, 61, 62). Potential benefit of this targeted approach to the 
treatment of HF lies in the ability of partial A1R agonism to afford protection to the failing 
myocardium by limiting triggers of cell injury and death. Furthermore, the prevention of 
deterioration of myocardial ATP levels matching the ATP production to oxygen supply seems 
to be an important factor for cardioprotection. Especially patients with high risk for cardiac 
events (e.g. HF patients with diabetes, chronic kidney disease [CKD], advanced CAD) might 
benefit from A1R activation.
Furthermore, excessive activation of the adrenergic nerve system is detrimental in HF 
patients, inducing systemic vasoconstriction, increased sodium / water retention, and 
ventricular remodeling, all of which contribute to disease progression. Adenosine carries anti-
adrenergic properties that can protect the heart from adverse mechanical and metabolic over-
response to excessive catecholamine stimulation, thereby limiting ischemia. Activation of the 
A1R may also inhibit norepinephrine release from cardiac presynaptic nerves (63, 64).
Conceivably, these effects may be important for preventing disease progression and further 
adverse remodeling, particularly in those patients with concomitant CAD. Partial adenosine 
A1R agonism might offer a unique opportunity to selectively modulate the sympathetic 
control of cardiac function via presynaptic A1R activation and cAMP inhibition (63). 
Heart failure is often associated with comorbidities like CKD and diabetes in HFpEF patients 
(65). Renal effects of adenosine A1R activation lead to vasoconstriction of the afferent 
arterioles in the kidneys (66) and thereby sodium retention and anti-diuretic effects. The 
effects were regarded as potential for renal benefit with adenosine antagonism in HF and led 
to large scale drug development programs with adenosine A1R antagonists, such as 
rolofylline in patients with acute decompensated heart failure (ADHF). But the Phase III trial 
failed to show any renal protection. Instead, higher rates of persistent renal impairment, 
seizure and stroke were noted in the rolofylline group (67, 68). In contrast, A1R activation 
shows reno-protective effects in preclinical models of ischemia-induced renal injury (69). 
Increased plasma levels of free fatty acids (FFAs) are often found in patients with HF (70, 71)
and result in an increase of insulin resistance and might be involved in the deterioration of 
heart function. A1R agonists can reduce plasma levels of FFAs in humans as shown in 
clinical trials (72). Furthermore, FFAs act as substrate for the energetic metabolism in the 
heart. HF is characterized by an added reliance on fatty acid oxidation, with downregulation 
of myocardial glucose transporters (73, 74). These changes characterize the transition of the 
failing heart to a fetal metabolic phenotype and gene profile, an adaptation that can further 
promote HF progression (73-75). Animal studies suggest that the partial A1R agonist 
capadenoson can augment expression of the GLUT-1 and GLUT-4 glucose transporters to 
near normal levels (50). Moreover, therapy with capadenoson has also been associated with 
normalization of protein levels that mediate fatty acid oxidation (50). Thus, A1R agonism 

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 20 of 85
appears capable of partially correcting derangements in cardiac substrate utilization and 
restoring a physiologic metabolic profile in HF.
Previous attempts to address the A1 receptor, while offering potential therapeutic benefits, 
were limited by undesirable side effects that include bradycardia, atrioventricular blocks, 
sedation and antidiuretic effects. Furthermore, adenosine-like A1R agonists often have the 
drawback of a short half-life and low bioavailability making them not suitable for chronic oral 
therapy.
In contrast, partial adenosine A1 agonists may be used to modulate and trigger primarily 
favorable pharmacological responses for HF therapy, such as cardio- and renoprotection. A 
partial agonist is a low efficacy ligand, which elicits only a submaximal response from the 
receptor in contrast to a full agonist, even when all receptors are occupied. A partial agonist is 
expected to result in a robust signal response only in tissues with relative high receptor 
reserve, whereas a full agonist will elicit a robust signal also in tissue with a low receptor 
reserve. Thus, partial agonists are useful for achieving high selectivity for the target 
organ / tissue and minimizing toxicity and effects in non-target tissues (e.g. neurological 
effects, undesired kidney effects, AV conduction abnormalities). Hemodynamic effects 
evoked by A1R activation seem to have a lower receptor reserve in e.g. the AV node 
compared to cardioprotective effects. Furthermore, partial adenosine A1R agonists might 
induce less receptor desensitization than full agonists and be ideal for chronic treatment (76).
3.3
Neladenoson bialanate
Neladenoson bialanate (BAY 1067197, which is the free base of the hydrochloride BAY 86-
8901) is the pro-drug of the pharmacologically active compound BAY 84-3174, a highly 
potent and selective non-adenosine like partial adenosine A1 receptor agonist suitable for 
once daily oral use.
Pharmacological actions seem to be at least partly based on an acute restoration and improved 
utilization of myocyte energetics (ATP production within the mitochondria), and chronic 
improvement of calcium handling by restoration of SERCA2a protein levels, which result in 
protection of cardiac function and improvement of contraction / relaxation coupling. These 
effects were seen after a short treatment period of one week in nonclinical models. In 
addition, neladenoson bialanate was characterized regarding mitochondrial function in 
isolated cardiomyocytes from normal and HF dogs (EF ~30%) produced by intracoronary 
microembolization as described in Sabbah et al (77). Neladenoson bialanate improved 
mitochondrial function (respiration, ATP synthesis, ATP / adenosine diphosphate [ADP] ratio, 
cytochrome c-dependent cyclooxygenase activity, membrane potential, and mitochondrial 
permeability transition pore opening) significantly and dose dependently in HF 
cardiomyocytes but had no effect on normal cardiomyocytes. Since both impaired myocardial 
energetics and disturbed calcium reuptake are considered key contributors to the 
pathophysiology of HFpEF, neladenoson bialanate has the potential to be a suitable treatment 
option for HFpEF patients to improve symptomatic status, morbidity and survival.
Furthermore, up to 80% of HFpEF patients are on a ß-blocker to optimize treatment of 
comorbidities, such as CAD or hypertension (29). However, ß-blockers can exacerbate 
chronotropic incompetence, an important cause of exercise intolerance in patients with 
HFpEF found in 50-80% of patients (23, 78, 79). Other than ß-blockers, neladenoson 

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 21 of 85
bialanate shows no effects on heart rate in preclinical (39) and clinical models (49). Thus, it is 
a suitable option in patients with HFpEF, where a treatment not damping heart rate would be 
desirable.
Nonclinical data showed that neladenoson bialanate is cardio- and renoprotective at doses 
lower than needed to elicit the clinically relevant undesirable effects on heart rate, AV-
conduction, blood pressure, renal function and the central nervous system. 
In animal models and clinical studies in healthy volunteers, neladenoson bialanate
significantly reduces plasma levels of free fatty acids vs. placebo. Abnormal energetic activity 
in heart failure correlates inversely with plasma free-fatty-acid concentrations. The excess of 
fatty acids may adversely affect the myocardium and in HF may be associated with uncoupled 
respiration (80). 
Further details can be found in the investigator’s brochure (IB), which contains 
comprehensive information on the study drug. The IB in its most current version is available 
in the study file. 
3.4
Rationale of the study
The main limitations of using full A1R agonists in cardiovascular indications such as HF are 
undesired cardiac effects, such as bradycardia and higher degree AV block as well as negative 
cardiac inotropy and dromotropy. In contrast, preclinical data show that the partial adenosine 
A1R agonist neladenoson bialanate can be used to modulate and trigger primarily favorable 
pharmacological responses for HF therapy and avoid undesired effects such as AV conduction 
abnormalities and higher degree AV block. Nevertheless, based on the mode of action, there 
are theoretical concerns particularly with regard to undesired effects, such as bradycardia and 
higher degree AV block for an A1R agonist, which might be aggravated by concomitant use 
of heart rate decreasing drugs like ß-blockers.
The purpose of this clinical trial is to assess the safety, tolerability and the pharmacokinetic 
and pharmacodynamic response of 20 weeks’ treatment with neladenoson bialanate compared 
to placebo in patients with chronic HFpEF on appropriate therapy for specific co-morbidities 
and to find the optimal dose for a further Phase III trial. 
4.
Study objectives 
The objective of the study is to find the optimal dose of neladenoson bialanate for the Phase 
III trial by detecting and characterizing a significant dose-response relationship in the primary 
efficacy endpoint, absolute change from baseline in 6-minute walking distance (6MWD) at 20 
weeks, in patients with chronic heart failure with preserved ejection fraction (HFpEF), and by 
characterizing the safety, tolerability and pharmacodynamic effects of the compound when 
given in addition to appropriate therapy for specific co-morbidities.
An exploratory objective is to further assess pharmacokinetic parameters and blood and urine 
biomarkers.
For variables please see Section 10.3.1.
Considering the exploratory nature of phase II studies and the uncertainty around the most 
appropriate endpoints in HFpEF, the sponsor will take the totality of the data (including 
secondary / exploratory endpoints) into consideration regarding the benefit / risk assessment 
and the decision to move into phase III.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 22 of 85
5.
Study design
5.1
Design overview
Study 17582 is a multicenter, randomized, placebo-controlled, parallel group, double blind, 
dose-finding Phase II study. Figure 5—1 displays the overall study design. 
Figure 5—1: Study design overview
Abbreviations: CV = cardiovascular; ICF = informed consent form; W = week
Approximately 288 patients from approximately 90 study centers worldwide will be 
randomized to one of the active treatment dose arms or placebo, in addition to their 
background therapy (for details see Section 7).
The study will comprise a 1-week run-in period, 20-week treatment period, and a 6-week 
follow-up period (27 weeks total).
Patients will have site visits at Weeks -1, 0 (baseline), 4, 8, 12, 20 (end of treatment visit) and 
24 (safety follow-up visit). In addition, 2 phone calls at Weeks 2 and 26 will be made to 
assess patients’ safety, and one additional phone call – to remind the patients of AVIVO self-
application at Week 19.
6MWD test (including Borg CR 10 Scale) will be done during the run-in, to familiarize 
patients with the test, and at baseline, Week 8 and end of treatment / premature 
discontinuation visits. Safety will be monitored throughout the study. PK samples will be 
taken from all patients at dedicated time points. Biomarkers reflecting the pharmacodynamic 
activity of the drug will be examined, as well as candidate biomarkers that may predict drug 
response.
For detailed visit descriptions and rules for patients who discontinue study treatment earlier,
please see Sections 9.1 and 9.2. 
The anticipated duration of the study as a whole is approximately 19 months: this includes an 
anticipated recruitment period of 13 months followed by a run-in period of 1 week, a 
treatment period of 20 weeks and a follow-up period of 6 weeks after enrollment of the last 
patient into the trial.
W -1
Visit 1
W 4
Visit 4
W 8
Visit 5
W 12
Visit 6
W 2
Visit 3, 
phone call
W 20
Visit 7
W 24 
Visit 8
W 26
Visit 9
phone call
placebo
5 mg
10 mg
20 mg
30 mg
40 mg
Treatment
Follow up
W 0
Visit 2
W 19
Phone call
Run-in

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 23 of 85
5.2
Primary variable

Absolute change from baseline in 6MWD after 20 weeks of treatment.
For secondary and other variables please see Section 10.3.1.
5.3
Justification of the design
A parallel group design was chosen to compare five different once-daily dose regimens and 
one placebo arm to find the best dose for Phase III. Placebo control is used to control for 
observer and subject bias, and randomization – to control for assignment bias. Based on Phase 
I data in healthy volunteers and Phase II data in heart failure patients, a sequential dose 
escalation design was not deemed necessary for neladenoson bialanate since the safety profile 
of the compound could be verified in dose ranges up to 40 mg. Evidence of A1R target 
engagement could already be achieved in different tissues across different clinical trials with 
20 mg neladenoson bialanate. The dose range around 20 mg (5, 10, 30 and 40 mg) is to ensure 
different data points to feed the MCP mod predefined models and potential unforeseen 
variances. The doses studied will ensure a strong dose recommendation moving forward into
phase III. Safety of the subjects in this parallel study design will be closely monitored by a 
Data Monitoring Committee (DMC).
5.4
End of study
The end of the study as a whole will be reached as soon as the last visit of the last patient has 
occurred in all centers in all participating countries (EU and non-EU).
6.
Study population 
6.1
Inclusion criteria
Patients must meet all of the following inclusion criteria to be included in the study:
1. Men or women aged 45 years and older
2. Diagnosis of chronic heart failure (CHF), NYHA class II-IV (without evidence of a non-
cardiac explanation for dyspnea), LVEF ≥ 45% assessed by any imaging modality (e.g. 
echocardiography, cardiac magnetic resonance, cine levocardiography) within the 
previous 6 months with no significant change in clinical status suggesting potential for 
deterioration in ejection fraction. 
3. In the 6 months prior to run-in: 
a) Requirement of treatment with a diuretic 
AND
b) Elevated natriuretic peptides, defined as one of:
o
BNP ≥ 75 pg/mL or NT-proBNP ≥ 300 pg/mL (sinus rhythm)
o
BNP ≥ 200 pg/mL or NT-proBNP ≥ 900 pg/mL (atrial fibrillation)
AND

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 24 of 85
c) At least one of the following:
o
LA enlargement (LA diameter ≥ 3.9 cm, LA volume ≥ 55 mL, 
LAVI ≥ 29 mL/m2, or LAA ≥ 20 cm2) (assessed by local imaging)
o
LV hypertrophy (septal or posterior wall thickness ≥1.1 cm) (local imaging)
o
Elevated filling pressures (invasive assessment) at rest (PAWP ≥ 20 mmHg or 
LVEDP ≥ 15 mmHg) or with exercise (PAWP ≥ 25 mmHg) (historical records)
4. 6MWD ≥ 100 m and ≤ 550 m at Visit 2 (baseline)
5. Written informed consent signed before any study-specific procedure
6.2
Exclusion criteria
Patients who meet any of the following exclusion criteria will be excluded from the study:
1. Acute decompensated heart failure (defined as acute exacerbation of HF that may require 
IV therapy with diuretics, vasodilators or inotropic drugs and / or mechanical support) 
within the past 4 weeks
2. Initiation or dose modification of cardiovascular pharmacological therapy within the past 
2 weeks (dose modification of pre-existing diuretic / anticoagulant medication is allowed 
based on patient-specific needs)
3. Inability to exercise: wheelchair / scooter / walker dependent; dependent on supplemental 
oxygen
4. HF is not the primary factor limiting activity as indicated by the patient affirming #1, #2 
or #3 of the following questionnaire:
My ability to be active is most limited by:
#1 - Joint, foot, leg, hip or back pain
#2 - Unsteadiness or dizziness impairing daily mobility
#3 - Lifestyle, weather, or I just don’t like to be active
5. Previous diagnosis of HFrEF (LVEF < 40%)
6. Known clinically significant persistent coronary ischemia (based on medical history, a 
preexisting or a recent clinical stress test)
7. Occurrence of any of the following within the previous 3 months:
o
Clinically evident myocardial infarction
o
Hospitalization for unstable angina
o
Stroke or transient ischemic attack
o
Coronary artery bypass graft (CABG) 
o
Percutaneous coronary intervention (PCI)
o
Implantation of a cardiac resynchronization therapy device (CRTD)
o
Major surgery (that could interfere with patients’ ability to exercise)

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 25 of 85
8. PCI, CABG or implantation of a CRTD planned between randomization and end of study
9. Sustained 1 systolic blood pressure ≤ 90 mmHg and / or signs and symptoms of 
hypotension prior to randomization
10. Sustained 1 systolic blood pressure ≥ 160 mmHg prior to randomization
11. Sustained 1 bradycardia with heart rate < 50 beats/minute or tachycardia with heart rate 
> 100 beats/minute prior to randomization 
12. Known clinically relevant ventricular arrhythmias (sustained ventricular tachycardia, 
ventricular flutter or fibrillation) within 3 months prior to randomization based on either 
medical history or device generated data (if applicable)
13. Clinically relevant permanent or intermittent AV-block > grade II in patients without a 
permanent pacemaker or ICD / CRTD
14. Severe uncorrected valvular heart disease
15. Listing for heart transplantation and / or anticipated implantation of a ventricular assist 
device
16. Severe pulmonary disease with any of the following:
o
Requirement of continuous (home) oxygen or 
o
History of chronic obstructive pulmonary disease ≥ GOLD III 
o
Use of systemic corticosteroids
17. Asthma bronchiale with any of the following:
o
Symptoms not well-controlled within the past 6 months or
o
Ever intubated or in an intensive care unit for asthma
18. Anemia with hemoglobin < 10 g/dL within 3 months prior to randomization. If several 
values are available the latest result should be used. 
19. Body mass index (BMI) > 45 kg/m2 at randomization
20. Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 calculated by 
Modification of Diet in Renal Disease (MDRD) formula within 3 months prior to 
randomization (see Appendix 16.1). If several values are available the latest result should 
be used.
21. Hepatic insufficiency classified as Child-Pugh B or C (see Appendix 16.2), or any of the 
following: 
o
Primary biliary cirrhosis (PBC)
o
Primary sclerosing cholangitis
o
PBC-autoimmune hepatitis overlap syndrome
                                                
1 At two consecutive visits

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 26 of 85
22. Concomitant use of any of the following therapy that cannot be discontinued:
o
Moderate or strong CYP3A4 inhibitors (Of note: grapefruit is a strong CYP3A4 
inhibitor)
o
CYP3A4 inducers
o
Strong CYP2C8 inhibitors (Of note: clopidogrel is a strong CYP2C8 inhibitor)
o
Theophylline
o
Drugs having significant pre-systemic clearance via UGT1A1 in the intestine
Respective substances must be stopped at least 7 days before randomization.
23. Women of childbearing potential (women are considered of childbearing potential if they 
are not surgically sterile or postmenopausal, defined as amenorrhea for > 12 months)
24. Known current heavy alcohol consumption or the use of illicit drugs that may interfere 
with the patient’s safety and / or compliance
25. Previous (within 30 days or 5 half-lives of the investigational drug, whichever is longer) 
or concomitant participation in another clinical study with investigational medicinal 
product(s) or device(s)
26. Previous assignment to treatment during this study
27. Any condition or therapy, which would make the patient unsuitable for the study, or life 
expectancy less than 12 months (e.g. active malignancy)
28. Close affiliation with the investigational site; e.g. a close relative of the investigator, 
dependent person (e.g. employee or student of the investigational site)
29. Known allergies, intolerance or hypersensitivities to the study treatment (active substance 
or excipients), adhesives or hydrogel
6.3
Justification of selection criteria
The selection criteria were chosen to exclude patients from the study who 1) may potentially 
be exposed to specific risks after administration of the study drug, 2) have conditions that may 
have an impact on the aim of the study, or 3) have a condition other than HFpEF that may be 
primarily responsible for their symptoms.
6.4
Withdrawal of patients from study
Withdrawal
6.4.1
An excessive rate of withdrawals (either patients discontinuing study medication or study 
withdrawal) can render the study non-interpretable. Therefore, un-necessary withdrawal of 
patients should be avoided and all efforts should be taken to motivate patients to comply with 
all the study specific procedures and to be followed until the end of the trial to detect the 
occurrence of cardiovascular events / assess vital status.
Before permanently discontinuing study medication (either initiated by the patient or the 
investigator) an interruption should be considered. Patients, who have temporarily 
discontinued study medication for any reason, should restart as soon as medically justified in 

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 27 of 85
the opinion of the investigator; the patient can re-start at any time before the end of treatment 
(EOT) visit. In addition, patients should not be withdrawn from the study drug or from the 
study solely for reaching a potential cardiovascular event. 
All patients who permanently discontinue study medication should come in for the 
EOT / premature discontinuation visit as soon as possible after discontinuation of the study 
medication and the safety follow-up visit 4 weeks after the last dose. In addition, they will be 
contacted by the investigator via the scheduled Week 26 phone call to assess occurrence of 
cardiovascular events.
The investigator should show due diligence and explore all possible options to reach a patient 
who fails to return to a visit. The site must document all attempts to try to contact the patient 
in the medical records / source documents.
In order to avoid loss-to-follow-up, the investigator should ask the patient at the study start for 
the contact details of a relative or friend who can be contacted in case the patient cannot be 
reached.
Patients should not be withdrawn from follow-up unless the patient explicitly withdraws 
consent to be contacted. All efforts should therefore be made to minimize the number of 
patients who withdraw such consent as, in general, no further information on cardiovascular 
events and survival status may be collected after that point.
Withdrawal criteria
Patients must be withdrawn from the study if any of the following occurs:

At their own request or at the request of their legally acceptable representative. At any 
time during the study and without giving reasons, a patient may decline to participate 
further. The patient will not suffer any disadvantage as a result.
Patients may be withdrawn from the study if any of the following occurs:

If, in the investigator's opinion, continuation of the study would be harmful to the 
patient's well-being.

At the specific request of the sponsor and in liaison with the investigator (e.g. obvious 
non-compliance, safety concerns).

If any investigational drug other than the study drug is used during the study period.
Depending on the time point of withdrawal, a withdrawn patient is referred to as either 
“screening failure” or “dropout” as specified below.
Screening failure
A patient who, for any reason (e.g. failure to satisfy the selection criteria), terminates the 
study before randomization is regarded a “screening failure”. 
Re-screening is allowed once and only in the following cases:

The patient had successfully passed the screening procedures, but could not be 
randomized to treatment on schedule.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 28 of 85

Initial screening occurred too early to complete the required washout period for
prohibited substances.
In any case, the investigator has to ensure that the repeated screening procedures do not 
expose the patient to an unjustifiable health risk. For re-screening, the patient must sign a new 
informed consent form, even if its version was not changed after the patient’s previous 
screening. In the event of re-screening the patient will be assigned a new patient identification 
number.
Dropout
A patient who discontinues study participation prematurely for any reason is defined as a 
“dropout” if the patient has already been randomized whether or not any study medication 
was taken.
General procedures
In all cases, the reason for withdrawal must be recorded in the CRF and in the patient's 
medical records. 
The patient may object to the generation and processing of post-withdrawal data as specified 
in Section 13.4.
Details for the premature termination of the study as a whole (or components thereof) are 
provided in Section 12.
Replacement
6.4.2
Randomized patients who drop out or withdraw prematurely will not be replaced.
6.5
Patient identification
The patient number is a 9-digit number consisting of:
Digits 1 to 5 
=  Unique center number
Digits 6 to 9
=  Current patient number within the center
7.
Treatments
7.1
Treatments to be administered
Patients will receive either active treatment with neladenoson bialanate or placebo; treatment
assignment is described in Section 7.3. Patients will be instructed to take two study tablets 
once daily, preferably in the morning, over a period of 20 weeks. On visit days, the study drug 
should be taken as specified in Table 9—1. The study drug should be taken with a glass of 
water, and can be taken with or without food. There will be no dose modifications; patients 
will stay on the dose which they were randomized to. For guidance regarding drug 
discontinuation please see Section 6.4.1
This treatment will be in addition to patients’ regular treatment of specific co-morbidities (see 
Section 8.1.2).

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 29 of 85
7.2
Identity of study treatment
Three different “BAY-numbers” are used within this document, corresponding to three 
different chemical appearances of neladenoson bialanate:
BAY 1067197 is a pro-drug. BAY 1067197 represents the “pharmaceutical principle” of 
neladenoson bialanate, and thus this BAY number is used when generally speaking about 
neladenoson bialanate. Present dosages refer to BAY 1067197.
BAY 86-8901 is the hydrochloride salt of BAY 1067197. BAY 86-8901 is used to formulate 
the immediate release tablets to be administered to study patients. This BAY number is used 
when speaking about the oral preparation of neladenoson bialanate.
BAY 1067197 cannot be found in measurable concentrations, or only at very low 
concentrations in the blood plasma. Orally administered drug is converted by ester cleavage 
into the active metabolite BAY 84-3174, which is responsible for the pharmacodynamic 
effects. BAY 84-3174 is used in the context of plasma pharmacokinetic data measurements.
Details of BAY 1067197 are given in Table 7—1; details of placebo are given in Table 7—2. 
For more information please refer to the latest available version of the investigator’s brochure. 
Table 7—1: Identity of neladenoson bialanate (BAY 1067197)
Sponsor’s internal 
reference number
BAY 1067197
Formulation
Pink coated tablets 
Galenical form
Round biconvex, diameter 8 mm 
Markings: One side PT; Other side blank
Composition
Active ingredient: neladenoson bialanate hydrochloride, 2-{4-[2-({[2-(4-
chlorophenyl)-1,3-thiazol-4-yl]methyl}sulfanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-
4-yl]phenoxy}ethyl L-alanyl-L-alaninate hydrochloride (BAY 86-8901)
Empirical formula: C35 H34 Cl N7 O4 S2 * HCl
Molecular mass: 716.29 + 36.46 [g/mole]
Excipients: Lactose anhydrous, Crospovidone and magnesium stearate
Coating: Lacquer pink (Opadry Pink 02A34744)
Strength
5 mg,10 mg and 20 mg
Packaging
Blister
Table 7—2: Identity of placebo
Formulation
Pink coated tablets 
Galenical form
Round, biconvex, diameter 8 mm 
Markings: One side PT; Other side blank
Composition
lactose monohydrate, cellulose microcrystalline and magnesium stearate
Coating: Lacquer pink (Opadry Pink 02A34744)
Packaging
Blister
Storage requirements
Study drug will be stored at the investigational sites according to the label requirements in a 
place inaccessible to unauthorized personnel, i.e. in a locked cabinet. 
All study drugs will be labeled according to the requirements of local law and legislation. 
Label text will be approved according to the sponsor’s agreed procedures, and a copy of the 
labels will be made available to the study site upon request.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 30 of 85
For all study drugs, a system of numbering in accordance with all requirements of GMP will 
be used, ensuring that each dose of study drug can be traced back to the respective bulk batch 
of the ingredients. Lists linking all numbering levels will be maintained by the sponsor’s 
clinical supplies quality assurance group. 
A complete record of batch numbers and expiry dates of all study treatment as well as the 
labels will be maintained in the sponsor’s study file.
7.3
Treatment assignment
The intention is to randomize approximately 288 patients to the doses 5 mg, 10 mg, 20 mg, 
30 mg, 40 mg of neladenoson bialanate, and placebo according to an allocation ratio of
1:2:2:2:2:3, respectively.
At the baseline visit, the investigator will first perform all required pre-treatment 
examinations and will then randomize the qualified patients to one of the six treatment arms. 
The randomization will be stratified by atrial fibrillation (AF): yes vs. no. 
Enrollment into the AF stratum may be stopped (after the discussion between the sponsor and 
the Steering Committee) when the AF stratum constitutes 30% of the total expected 
enrollment.
The randomization lists will be provided by Bayer’s Global Randomization Management 
Group. Randomization will be done using an interactive voice / web response system (IxRS).
A handbook describing how to use the IxRS will be provided to each study site.
7.4
Dosage and administration
For dosage and administration please refer to Section 7.1.
7.5
Blinding
All patients will receive the same number of tablets (only active, combination of active and 
placebo or only placebo, depending on the treatment arm) to maintain the blind (Table 7—3). 
Table 7—3: Assignment of tablets to dose groups
Treatment arm/ 
Formulation
5 mg
10 mg
20 mg
30 mg
40 mg
Placebo
5 mg
1
0
0
0
0
0
10 mg
0
1
0
1
0
0
20 mg
0
0
1
1
2
0
Placebo
1
1
1
0
0
2
Total tablets/day
2
2
2
2
2
2
The following parties will be unblinded: sponsor’s IxRS and Medication Manager, Clinical 
Supply Manager and Clinical Pharmacometrics analyst (who will be provided with a 
randomization list for selected bioanalyses of the active metabolite BAY 84-3174 in plasma), 
the Fisher Project Manager, and the independent DMC.
For all other sponsor’s study personnel, the Steering Committee and the Clinical Events
Committee (CEC) the blinding will be strictly kept.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 31 of 85
In compliance with applicable regulations, in the event of a SUSAR (see Section 9.6.1.5) 
related to the blinded treatment, the patient’s treatment code will usually be unblinded before 
reporting to the health authorities, ethic committees and investigators (see Section 9.6.1.4).
For exceptions please see Section 9.6.1.4.
Emergency unblinding by the investigator
In the event of emergency, and where knowledge of assigned treatment allocation is required 
for the acute treatment strategy, the investigator may unblind the case. Unblinding will be 
handled in IxRS.
The occurrence of SAEs should not routinely precipitate the immediate unblinding. The 
investigator is required to promptly document and explain to the sponsor any premature 
unblinding (e.g. unblinding due to an SAE) of the study drug. The investigator should report 
unblinding of treatment to the EC / IRB according to the EC / IRB’s requirements.
7.6
Drug logistics and accountability
All study drugs will be stored at the investigational site in accordance with GCP and GMP 
requirements and the instructions given by the clinical supplies department of the sponsor (or 
its affiliate), and will be inaccessible to unauthorized personnel. Special storage conditions 
and a complete record of batch numbers and expiry dates can be found in the sponsor’s study 
file; the site-relevant elements of this information will be available in the investigator site file. 
On the day of receipt, the responsible site personnel will confirm receipt of study drug via 
IxRS. The personnel will use the study drug only within the framework of this clinical study 
and in accordance with this protocol. Receipt, distribution, return and destruction (if any) of 
the study drug must be properly documented according to the sponsor’s agreed and specified 
procedures.
Written instructions on medication destruction will be made available to affected parties as 
applicable.
7.7
Treatment compliance
To monitor compliance, the investigator will be required to document drug dispensing for 
each patient. Overall compliance with study drug intake should be between 80% and 120% of 
the scheduled dose at the end of study drug treatment. The date of dispensing the study drug 
to the patient will be documented.
Study drug will be dispensed according to the schedule provided in Section 9.1.
Patients will return at scheduled visits or at the premature discontinuation / EOT visit, if 
applicable, with all remaining unused study drug, when accountability will be determined for 
all tablets. To facilitate this, patients must be instructed to return all of the study drug 
packaging including unused study drug and empty packaging.
Any discrepancies between actual and expected amount of returned study medication must be 
discussed with the patient at the time of the visit, and any explanation must be documented in 
the source records.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 32 of 85
8.
Non-study therapy 
8.1
Prior and concomitant therapy
Prohibited concomitant medication
8.1.1
Concomitant therapy with any of the following drug classes is prohibited:

Moderate or strong CYP3A4 inhibitors (Of note: grapefruit is a strong CYP3A4 
inhibitor)

CYP3A4 inducers

Strong CYP2C8 inhibitors (Of note: clopidogrel is a strong CYP2C8 inhibitor)

Theophylline

Drugs having significant pre-systemic clearance via UGT1A1 in the intestine
Respective substances must be stopped at least 7 days before randomization and can only be 
started 6 weeks after the last intake of study drug. A list of prohibited medications will be 
provided to the investigators.
If a prohibited concomitant medication (e.g. moderate / strong CYP3A4 inhibitor) is used 
during the study conduct, the study drug should be interrupted immediately and restarted as 
soon as possible, when the prohibited medication has been stopped. Prior to re-starting the 
study drug, a washout period of at least two days after discontinuation of the prohibited 
medication should be adhered to.
Permitted therapy
8.1.2

All patients should be treated for specific co-morbidities as considered appropriate by 
the investigator and in accordance with standard therapy guidelines.

Concomitant therapy is allowed unless listed in the prohibited medication section.
During the treatment period the background medications should be kept stable and changes in 
treatment should be based on clinical need.
Neladenoson bialanate is a weak BCRP inhibitor. The risk of clinically relevant drug–drug 
interactions at doses up to 40 mg BAY 1067197 due to inhibition of BCRP is regarded as low, 
but cannot be excluded (BCRP substrates are atorvastatin, simvastatin, rosuvastatin, 
fluvastatin, methotrexate, etc.; a list of BCRP substrates will be made available to the 
investigators).
If neladenoson bialanate is given concomitantly with other drugs that may increase the 
exposure of BCRP substrates, the respective drug labels should be consulted.
All concomitant medication will be documented in the eCRF.
8.2
Post-study therapy
The investigator must provide follow-up medical care for all patients who complete the study 
or who are prematurely withdrawn from the study, or must refer them for appropriate ongoing 
care, as required.
Study medication will not be available to patients after completion of the study.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 33 of 85
9.
Procedures and variables
9.1
Tabular schedule of evaluations

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 34 of 85
Table 9—1: Schedule of evaluations
Study period
Run-
in
Treatment a
EOT /
PDV
Safety 
FU

Unscheduled e
Visit number
1
2
3
4
5
6
7
8
9
Visit type
site
site

site
site
site
b
site
site

Week
Day and allowed deviations
-1
-7
W0
0+2
W2
14±2
W4
28±2
W8
56±2
W12
84±2
W19
133-2
W20 a
140±2
W24 c
168±2
W26 a
182+7
pre-rand.
Signed informed consent 
●
Inclusion / exclusion criteria
●
●
KCCQ
●
●
●
●
EQ-5D-5L
●
●
Demographic data
●
Medical and surgical history
●
Smoking & alcohol history
●
Caffeine & chocolate 
consumption
●
●
Physical exam
●
●
●
●
●
●d
●
Height
●
Weight
●
●
●
●
●
●
●
12-lead ECG 
●
●
●
NYHA class 
●
●
●
●
●
●
●
BP and heart rate
●
●
●
●
●
●
●
●
Adverse events
●
●
●e
●
●
●
●
●
●e
●
Concomitant medication 
●
●
●
●
●
●
●
●
●
●
6MWD test, Borg CR 10 
Scale
●f
●g
●
●
Echocardiography (central)
●
●
AVIVO application, worn for 
7 days
●
●
●
h
●
Collection of AVIVO device
●
●
●
●
Randomization via IxRS
●
post-rand.
Laboratory (central lab)
Blood sample for safety 
pre-dose
●
●
●
●
●
●
Blood sample for biomarkers
pre-dose
●
● 
●i
Urine sample for biomarkers
pre-dose
●
●
PK sample (exact time to be 
documented) j
2h
post-dose
pre-
dose
pre-
dose
~2h & 4h 
post-dose
1 day    
post-dose
●
Study drug k
Study drug intake at the site
●
●
●
Study drug intake before the 
visit
~2h before
1 day 
before
Patients to remember the 
time of the study drug 
intake 
day 
before
day 
before
●
day of    
last dose
Dispense contact card 
●
Dispense study drug 
●
●
●
●
Collect unused study drug 
●
●
●
●
6MWD = 6-minute walking distance; BP = blood pressure, ECG = electrocardiogram; EOT = end of treatment; EQ-5D-5L = 
EuroQol Group 5-dimensional, 5-level questionnaire; FU = follow-up; h = hour(s); IxRS = interactive web/voice response 
system; KCCQ = Kansas City Cardiomyopathy Questionnaire; NYHA = New York Heart Association; PDV = premature 
discontinuation visit; post-rand. = post-randomization; PK = pharmacokinetics; pre-rand. = pre-randomization; W = week

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 35 of 85
Table 9-1: Schedule of evaluations (continued)
a For patients who discontinue study medication prematurely:

EOT / premature discontinuation visit must be performed as soon as possible after 
discontinuation of the study drug.

Safety FU visit must be scheduled 4 weeks after the last dose (± 2 days). 

Week 26 follow-up call will be made 26 weeks after the start of treatment (+7 days). 
b Phone call to remind patients to self-apply AVIVO device. The phone can be made up to 2 days 
before Week 19, but not later than Week 19, to have 7 days of data for evaluation at the Week 20 
visit.
c Safety FU visit is relative to the last dose of study medication and is 4 weeks after the last dose.
d Targeted physical examination based on symptoms
e If there is an AE reported during a phone call, the investigator, at his / her discretion, may ask the 
patient to come for an unscheduled visit at the patient’s earliest convenience (Section 9.2.11).
f 6MWD test (including Borg CR 10 Scale) at Visit 1 (run-in visit) is to familiarize patients with the test.
g Patients are only allowed to be randomized, if the walking distance determined at Visit 2 (Week 0) is 
≥ 100 m and ≤ 550 m; the distance walked in the familiarization test at run-in (Week -1) will not be 
taken into account to decide if patients can move forward to randomization.
h At Visit 6 (Week 12) the site will hand over an AVIVO device to patients for self-application at Week 
19 and instruct them how to apply the device 
i Only NT-proBNP 
j At Visit 2: One PK sample will be drawn not earlier than 2 hours and not later than 6 hours after the 
first dose of study medication. The exact time of the first dose must be recorded by the investigator.
At Visits 4 and 5: One PK sample at each of the visits will be drawn pre-dose. Patients must not 
take study medication before the visit but should remember the exact time of the previous dose.
At Visit 6: Two PK samples will be drawn post-dose 
1.
2 hours after the study drug intake (range 1:30 hour to 3:29 hours)
2.
4 hours after the study drug intake (range 3:30 hours to 5:30 hours)
The minimum time between the two samples should be at least 1 hour.
Patients will be instructed to take the study drug about 2 hours before the visit and to remember 
the exact time. If a patient does not take the study drug before the visit, he / she can take it at the 
start of the visit, in which case PK sampling will occur as described above. 
At Visit 7: One PK sample will be drawn 1 day after the last dose. Patients should remember the 
exact time of their last dose.
k It is important that the patients remember the time of the tablet intake as precisely as possible (i.e. 
exact hour and minute) on the following days:
1.
On the day before Visits 4 and 5
2.
On the day of Visit 6
3.
On the day of their last dose
This information will be recorded in the patient’s file. A phone call to remind the patients is 
recommended. The investigator must record the time of the dose when the study drug is taken at the 
site.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 36 of 85
9.2
Visit description
Visit 1 (Week -1, run-in)
9.2.1

Confirm signed informed consent is available (Section 13.4)

Allocate unique patient identification number (Section 6.5)

Eligibility assessment (Sections 6.1 and 6.2)

Demographic data collection and recording (Section 9.3.1)

Blood pressure and heart rate measurement (Section 9.6.3.4) 

Adverse events assessment (Section 9.6.1.3)

Concomitant medication collection and recording (Section 8.1)

6MWD test, to familiarize the patient with the procedure (Section 9.4.1)

Borg CR 10 Scale (Section 9.4.2)

AVIVO device application, worn for 7 days (Section 9.6.3.5)

Contact card dispensing
Visit 2 (Week 0, baseline)
9.2.2
At Visit 2 eligibility must be re-assessed before the patient is randomized to a treatment arm. 
Please note: laboratory eligibility criteria are based upon local historical records, not central 
laboratory findings. Even retrospectively, central laboratory results from the baseline visit will 
not render a patient ineligible for the study. If a patient is not eligible for randomization, or 
withdraws for other reasons before randomization, he / she will be considered a screening
failure even though the visit is not named a screening visit (for details see Section 6.4.1).
The following procedures will be performed before randomization:

Review in/exclusion criteria and confirm patient eligibility

Quality of life questionnaires (KCCQ and EQ-5D-5L), to be completed by the patient
(Section 9.4.6)

Medical and surgical history collection and recording (Section 9.3.2)

Tobacco smoking and alcohol history collection and recording

Assessment of caffeine-containing beverage and chocolate consumption during the 
previous 4 weeks

Physical examination (Section 9.6.3.2)

Weight and height measurement (BMI will be calculated automatically)

12-lead ECG (Section 9.6.3.3)

NYHA class assessment (Section 9.4.5.2)

Blood pressure and heart rate measurement (Section 9.6.3.4)

Adverse events assessment (Section 9.6.1.3)

Concomitant medication collection and recording (Section 8.1)

6MWD test (Section 9.4.1)

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 37 of 85

Borg CR 10 Scale (Section 9.4.2)

Collection of AVIVO device applied at Visit 1 (Week -1)

Echocardiography (Section 9.4.3)

AVIVO device application, worn for 7 days (Section 9.6.3.5)
After all above procedures are done, the patient can be randomized via IxRS (Section 7.3).
The following procedures should be performed after randomization and before study 
medication intake:

Blood sampling for safety (Section 9.6.3.1). 

Blood and urine sampling for biomarkers (Section 9.4.4)

Study drug dispensing (Section 7.7)
The following procedures should be performed during and after study medication intake:

Start of study medication (Section 7.1). The first dose of study medication will be 
taken after all previous procedures are completed; the time of intake should be 
recorded. The patients will be instructed to remember the time of medication intake as
precisely as possible on selected days.

PK sampling not earlier than 2 hours and not later than 6 hours after the first dose of 
study medication; the exact time of PK sampling and drug intake is to be documented
in the patient’s file (Section 9.5).
Visit 3 (Week 2, phone call)
9.2.3
After 2 weeks of treatment (± 2 days) the site personnel will call the patient to inquire about 
adverse events and to collect information on concomitant medications. If there is an AE 
reported during the phone call, the investigator may ask the patient to come for an 
unscheduled visit (Section 9.2.11). Information collected during the phone call must be 
recorded in the patient’s medical records / source documents.
Visit 4 (Week 4)
9.2.4

Quality of life questionnaire (KCCQ), to be completed by the patient (Section 9.4.6)

Physical examination (Section 9.6.3.2) 

Weight measurement

NYHA class assessment (Section 9.4.5.2)

Blood pressure and heart rate measurement (Section 9.6.3.4)

Adverse events assessment (Section 9.6.1.3)

Concomitant medication collection and recording (Section 8.1)

Collection of AVIVO device applied at Visit 2 (Week 0)

Blood sampling for safety (Section 9.6.3.1)

PK sampling (pre-dose). Please note: on this day the patient should not take the study 
medication before the visit but only after the PK sampling. Ideally, the study 

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 38 of 85
personnel should contact the subject prior to Visit 4 to remind them not to take the 
study drug as usual in the morning at home. The patient should remember the time of 
the previous study drug intake as precisely as possible. The exact time of PK sampling 
and drug intake is to be documented in the patient’s file.

Blood and urine sampling for biomarkers (Section 9.4.4)

Study drug dispensing and unused study drug collection (Section 7.7)
Visit 5 (Week 8)
9.2.5

Physical examination (Section 9.6.3.2)

Weight measurement

NYHA class assessment (Section 9.4.5.2)

Blood pressure and heart rate measurement (Section 9.6.3.4)

Adverse events assessment (Section 9.6.1.3)

Concomitant medication collection and recording (Section 8.1)

6MWD test (Section 9.4.1)

Borg CR 10 Scale (Section 9.4.2)

AVIVO device application, worn for 7 days (Section 9.6.3.5)

Blood sampling for safety (Section 9.6.3.1)

PK sampling (pre-dose). Please note: on this day the patients should not take the study 
medication before the visit but only after the PK sampling. Ideally, the study personnel 
should contact the subject prior to Visit 5 to remind them not to take the study drug as 
usual in the morning at home. The patient should remember the time of the previous 
study drug intake as precisely as possible. The exact time of PK sampling and drug 
intake is to be documented in the patient’s file.

Study drug dispensing and unused study drug collection (Section 7.7)
Visit 6 (Week 12)
9.2.6

Quality of life questionnaire (KCCQ), to be completed by the patient (Section 9.4.6)

PK sampling (Section 9.4.6.2):
o Study drug is to be taken at home approximately 2 hours before the visit; it is 
important that the patient remembers the time of study drug intake as precisely as 
possible; a phone call on the previous day to remind the patient is recommended.
This information will be documented in the patient’s file.
o The first PK sample is to be taken approximately 2 hours after study drug intake
(range 1:30 hour to 3:29 hours). Time of sampling should be precisely 
documented in the patient’s file.
o The second PK sample is to be taken approximately 4 hours after study drug
intake (range 3:30 hours to 5:30 hours). Time of sampling should be precisely 
documented in the patient’s file.
o The minimum time between the two samples should be at least 1 hour.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 39 of 85
If a patient does not take the study drug before the visit, he / she can take it at the start 
of the visit, in which case PK sampling will occur as described above.

Physical examination (Section 9.6.3.2)

Weight measurement

12-lead ECG (Section 9.6.3.3)

NYHA class assessment (Section 9.4.5.2)

Blood pressure and heart rate measurement (Section 9.6.3.4)

Adverse events assessment (Section 9.6.1.3)

Concomitant medication collection and recording (Section 8.1)

Collection of AVIVO device applied at Visit 5 (Week 8) 

Handing-over AVIVO device to patients for self-application at Week 19 (Section 
9.2.7) and instruction of patients how to apply the device

Blood sampling for safety (Section 9.6.3.1). 

Study drug dispensing and unused study drug collection (Section 7.7)
Reminder phone call at Week 19
9.2.7
After 19 weeks of treatment (- 2 days) the site personnel will call the patients to remind them 
to self-apply the AVIVO device provided at Visit 6 (Week 12); if the device has not been 
provided at site, it should have been shipped to the patients. If there is an AE reported during 
the phone call, the investigator will have to make sure this is further assessed at the Week 20 
visit or at an unscheduled visit prior to this. Information collected during the phone call must 
be registered in the patient’s medical records / source documents.
Every effort should be made that the Week 20 visit at the site is conducted 7 days after the 
patient has applied the AVIVO device to have 7 days of data for evaluation. Accordingly, 
scheduling of Week 19 reminder-call and Week 20 visit should be aligned to achieve this. If 
the site prefers to have an on-site visit at Week 19 for the purposes mentioned above, an 
unscheduled visit (Section 9.2.11) can be conducted instead of the phone call (the patient’s 
preference should also be considered).
Visit 7 (Week 20, EOT or premature discontinuation) 
9.2.8
The last dose of study drug should be taken the day before the visit. The patients should 
remember the time of the last dose as precisely as possible; this information will be recorded 
in the patient’s file. It is recommended to make a reminder phone call to the patients on the 
previous day.
If a patient discontinues study treatment prematurely this visit should be completed as soon as 
possible after the last dose.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 40 of 85

Quality of life questionnaires (KCCQ and EQ-5D-5L), to be completed by the patient 
(Section 9.4.6)

Physical examination (Section 9.6.3.2)

Weight measurement 

Assessment of caffeine-containing beverage and chocolate consumption during the 
previous 4 weeks

12-lead ECG (Section 9.6.3.3)

NYHA class assessment (Section 9.4.5.2)

Blood pressure and heart rate measurement (Section 9.6.3.4)

Adverse events assessment (Section 9.6.1.3)

Concomitant medication collection and recording (Section 8.1)

6MWD test (Section 9.4.1)

Borg CR 10 Scale (Section 9.4.2)

Collection of AVIVO device applied at Week 19

Echocardiography (Section 9.4.3)

Blood sampling for safety (Section 9.6.3.1). 

PK sampling one day after the last dose (Section 9.4.6.2).

Blood and urine sampling for biomarkers (Section 9.4.4)

Unused study drug collection (Section 7.7)
Visit 8 (Week 24, safety follow-up)
9.2.9
If a patient discontinues study treatment prematurely this visit should be completed 4 weeks 
±2 days after the last dose.

Physical examination (targeted examination based on symptoms) (Section 9.6.3.2)

Weight measurement 

NYHA class assessment (Section 9.4.5.2)

Blood pressure and heart rate measurement (Section 9.6.3.4)

Adverse events assessment (Section 9.6.1.3)

Concomitant medication collection and recording (Section 8.1)

Blood sampling for safety (Section 9.6.3.1)

PK sampling (Section 9.4.6.2)

Blood sampling for NT-proBNP (Section 9.4.4)

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 41 of 85
Visit 9 (Week 26, phone call)
9.2.10
Twenty-six weeks after the start of study treatment the site personnel will call the patients to 
inquire about adverse events, including cardiovascular events, and to collect information on 
concomitant medications. For patients who discontinue study drug treatment early, the phone 
call will still be made 26 weeks after the start of study treatment. Information collected during 
the phone call must be recorded in the patient’s medical records / source documents.
Unscheduled Visit 
9.2.11
If a patient experiences an adverse event for which the investigator determines a follow-up 
site visit is necessary (either before the next scheduled study visit or during the Week 26
phone call), then the following assessments will be performed:

Physical examination (Section 9.6.3.2)

Weight measurement 

NYHA class assessment (Section 9.4.5.2)

Blood pressure and heart rate measurement (Section 9.6.3.4)

Adverse events assessment (Section 9.6.1.3)

Concomitant medication collection and recording (Section 8.1)

Blood sampling for safety (Section 9.6.3.1)
9.3
Population characteristics
Demographic and vital signs
9.3.1
The following demographic and vital signs data will be collected and recorded in the eCRF:

Year of birth

Age (to be calculated by the investigator)

Gender

Race / ethnicity (collection may be restricted per local regulations)

Weight

Height
BMI will be calculated automatically.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 42 of 85
Medical history
9.3.2
Medical history findings (i.e. previous diagnoses, diseases or surgeries) meeting all criteria 
listed below will be collected as available to the investigator:

Start before signing of the informed consent 

Pertaining to the study indication

Considered relevant to the study (e.g. cardiovascular and metabolic diseases)

Considered relevant for the patient’s study eligibility

Related to concomitant medication
Detailed instructions on the differentiation between (i) medical history and (ii) adverse events 
can be found in Section 9.6.1.1.
Other baseline characteristics
9.3.3
In addition, the following baseline characteristics will be collected and recorded:

Pre-defined medical history

NYHA class

Tobacco smoking history

Alcohol consumption history

Recent caffeine-containing beverage and chocolate consumption history
9.4
Efficacy
6MWD test
9.4.1
The 6MWD test is designed to evaluate a patient’s exercise capacity while performing an 
everyday activity. During this study, a 6MWD test including Borg CR 10 Scale will be 
conducted at different time points as specified in Table 9—1, for further details on assessment 
refer to Section 16.3. A familiarization 6MWD test will be performed during the run-in phase. 
To avoid any interactions, it is not permitted to perform the familiarization test on the same 
day as the baseline (Week 0) 6MWD test. It is only allowed to randomize patients, if the 
walking distance determined at baseline is ≥ 100 m and ≤ 550 m.
Borg CR 10 Scale
9.4.2
The score on the Borg CR 10 Scale will always be measured in conjunction with the 6MWD 
test. For details on time points refer to Table 9—1, for further details on assessment refer to 
Section 16.4. 
The Borg CR 10 Scale will be explained to the patients before starting the 6MWD test 
(questionnaires and instructions will be provided in local language). Patients will be asked to 
rank their exertion at the end of the 6MWD test. If a patient has problems understanding the 
principles of rating, an attempt should be made to explain the principles in a neutral and 
unpersuasive manner. The test result will be entered on same work sheet as the 6MWD test 
result. Later on the results will be transferred into the eCRF. 

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 43 of 85
Echocardiography
9.4.3
Transthoracic echocardiography and tissue Doppler will be performed at the time points 
specified in Section 9.1. The readings will be assessed centrally. SBP, DBP, and HR will be 
measured during echocardiography in addition to acquisition of echo data. The following 
parameters (but not limited to) will be analyzed by the central reader:

LV ejection fraction (LVEF, %)

LV end-diastolic volume (LVEDV), LVEDV index (LVEDVI, calculated as 
LVEDV/BSA) 

LV end-systolic volume (LVESV), LVESV index (LVESVI, calculated as 
LVESV/BSA)

LA size (LA diameter, area, volume index [LAVI, calculated as LAV/BSA])

Lateral e' (early diastolic mitral annular relaxation velocity at the lateral mitral annulus 
by Tissue Doppler, TD)

Septal e' (early diastolic mitral annular relaxation velocity at septal mitral annulus by 
TD), including calculation of average e'

Global longitudinal strain (%)

Pulmonary artery systolic pressure (PASP), estimated by tricuspid regurgitation 
velocity and inferior vena cava diameter, including its change with respiration, and 
hepatic vein flow in patients with tricuspid regurgitation

Tricuspid annular plane systolic excursion (TAPSE), right ventricular (RV) s'
(velocity of the tricuspid annular systolic excursion at the RV free wall by TD)

Mitral regurgitation

LV mass, LV mass index (calculated as LV mass/BSA)

Wall thicknesses, incl. interventricular septum diameter (IVSD), posterior wall 
thickness (PWT), anteroseptal wall thickness (ASWT)

E, A (if in sinus rhythm), calculation of E/A and E/e' (using lateral, septal, average e') 
ratios

E-wave deceleration time (EWDT)

Stroke volume (SV, calculated by LVEDV - LVESV) and derived parameters, 
including SV index (SVI, calculated as SV/BSA), cardiac output (CO, calculated as 
SV*HR), cardiac index (CI, calculated as CO/BSA), systemic arterial compliance 
(SAC, calculated as SV/PP), total peripheral resistance (TPR, calculated as 
MAP/CO*80)

Effective arterial elastance (Ea), estimated as end-systolic pressure (Pes) [Pes 
calculated as SBP times 0.9 (82)] divided by SV (SBP*0.9/SV)
Final details of all echocardiography parameters to be measured and analyzed will be 
included in a separate echocardiography manual.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 44 of 85
Biomarker investigations
9.4.4
Biomarker investigations in the present study will include the biomarkers listed below. 
Mandatory (sampled at all time points): 
-
NT-proBNP (baseline disease status & efficacy)
-
High sensitivity troponin T (hs-TNT) (baseline disease status)
-
Cystatin C (baseline disease status & efficacy)
-
Free fatty acid (FFA) (target engagement / mechanistic marker)
-
Urine albumin-to-creatinine ratio (UACR)
-
Hemoglobin A1c (HbA1c) (target engagement / mechanistic marker)
-
Neutrophil gelatinase-associated lipocalin (NGAL) (baseline disease status & efficacy)
Additional exploratory biomarker sampling:
-
Soluble suppression of tumorigenicity-2 (sST2) (baseline disease status & efficacy)
-
Galectin-3 (Gal-3) (baseline disease status & efficacy)
-
Growth differentiation factor 15 (GDF-15) (baseline disease status & efficacy)
-
Mid-regional pro-atrial natriuretic peptide (MR-proANP) (baseline disease status & 
efficacy)
-
Copeptin (baseline disease status & efficacy)
-
Osteopontin (OPN) (baseline disease status & efficacy)
-
Tissue inhibitor of metalloproteinase-4 (TIMP-4) (baseline disease status & efficacy)
-
Additional newly emerging HF or safety biomarkers
Blood sampling for biomarkers is scheduled for the time points as given in Section 9.1. All 
biomarkers will be measured using validated assay systems. Quality control (QC) and 
calibration samples will be analyzed concurrently with study samples. The results of the QC 
samples will be reported in a separate analytical report. Details on the collection, processing, 
storage and shipment of biomarker samples will be provided in separate documents (e.g. 
sample handling sheets or lab manual). Additional exploratory biomarkers sampling is to be 
used for research purposes to identify and / or verify biomarkers that are predictive or 
correlate with the efficacy / safety and the response in terms of tolerability of neladenoson 
bialanate. The analysis of exploratory biomarker may include the listed above exploratory 
biomarkers, safety biomarkers or new emerging HF biomarkers. Exploratory biomarker 
statistics may be reported separately. Exploratory biomarker analysis completed in the first 
year after the end of the study will be reported back to the investigator, if this provides 
additional meaningful information. Pure exploratory measures without an established 
interpretation might be withheld of reporting, considering that this will be of no value to the 
investigator or patient. The steering committee will provide guidance to the sponsor on 
reporting of exploratory biomarkers to investigators and patients.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 45 of 85
In addition to the biomarkers listed above, other biomarkers deemed relevant to gain further 
knowledge about the pathomechanism of the disease or about the drug (i.e. mode of action 
related effect or safety of the drug) may be measured, based on newly emerging data from 
other ongoing studies and / or literature data.
Table 9—2: Sample types used for biomarker investigations
Sample type, short form
Description
Biomarker  serum
Blood sample for serum preparation for biomarker analysis
Biomarker  plasma 
Blood sample for plasma preparation for biomarker analysis
Biomarker  urine
Urine sample for biomarker analysis
Clinical efficacy variables
9.4.5
9.4.5.1
Clinical outcome events
The following clinical outcome events will be collected:

All deaths (CV and non-CV)

HF hospitalizations and urgent visits for HF

Myocardial infarction

Stroke
The CEC will adjudicate all deaths as either CV or non-CV, and other events listed above in 
accordance with the pre-specified endpoint criteria in the adjudication charter. Investigators 
are mandated to report all suspected potential endpoints for adjudication by the CEC.
Events for adjudication should be reported as soon as critical data (as defined in the eCRF 
page) to the event adjudication is available. A query will be posted for events that require 
additional supporting documentation from the sites in order to render an adjudicated result 
and will be followed up by the sponsor. Every effort will be made to provide the CEC with 
clean eCRF data and required clinical data prior to event adjudication.
9.4.5.2
NYHA class assessment
NYHA 
class
Symptoms
I
Patients with cardiac disease but without resulting limitation of physical activity. Ordinary physical 
activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain.
II
Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at 
rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.
III
Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable 
at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain.
IV
Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. 
Symptoms of heart failure or the anginal syndrome may be present even at rest. If any physical 
activity is undertaken, discomfort is increased.
Source: (83) 

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 46 of 85
Patient-reported outcomes
9.4.6
At study visits where the questionnaire is required (see Table 9—1), patients should complete 
it before any other study procedures or assessments.
At collection, the questionnaire will be reviewed for completeness, and the patient will be 
encouraged to answer any blank data fields. Subsequently, a member of the investigator’s 
team will enter the responses into the eCRF. Details about scoring and calculating algorithms 
will be provided in the statistical analysis plan (SAP).
9.4.6.1
KCCQ
The KCCQ is the leading health-related quality-of-life measure for patients with CHF. It was 
developed in the late 1990s to early 2000s by Dr. John Spertus at the Mid-America Heart 
Institute, Kansas City, MO, USA. It is a 23-item questionnaire that independently measures 
the impact of patients’ HF, or its treatment, on 7 distinct domains: 
1) Symptom Frequency – the KCCQ Symptom scale quantifies the frequency of clinical 
symptoms in HF, including fatigue, shortness of breath, paroxysmal nocturnal dyspnea, 
and edema / swelling.
2) Symptom Burden – the KCCQ Symptom burden scale quantifies the severity of clinical 
symptoms in HF, including fatigue, shortness of breath and edema / swelling.
3) Physical Limitation – the KCCQ Physical limitation scale measures the limitations 
patients experience, due to their HF, in performing routine activities.
4) Quality of Life – the KCCQ Quality of life scale is designed to reflect patients’ 
assessment of their quality of life, given the current status of their HF. 
5) Social Limitations – the KCCQ Social limitation scale quantifies the extent to which HF 
symptoms impair patients’ abilities to interact in social roles.
6) Self-efficacy – numerous studies have underscored the importance of patients being 
engaged in the management of their disease. The KCCQ Self-efficacy scale quantifies 
patients’ perception of how to prevent HF exacerbations and manage complications when 
they arise.
7) Symptoms Stability– unlike the other 5 domains that provide cross-sectional 
quantification of patients’ current status, the KCCQ Symptom stability domain measures 
recent changes in patients’ symptoms. As a measure of change, it is most interpretable as 
a baseline assessment of the stability of patients’ symptoms at the start of the study and 
thereafter.
In addition, there are 3 summary scores, a Total Symptom Score that combines the Symptom 
Frequency and the Symptom Burden scores, a Clinical Summary Score that combines the 
Total Symptom and Physical Limitation scores to replicate the NYHA classification; and an 
Overall Summary Score that includes the Total Symptom, Physical Limitation, Social 
Limitations, and Quality of Life scores (Figure 9—1).

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 47 of 85
Figure 9—1: KCCQ Scores
9.4.6.2
EQ-5D-5L
The EQ-5D-5L consists of 2 pages: the EQ-5D-5L descriptive system and the EQ visual 
analogue scale (EQ VAS). The EQ-5D-5L descriptive system comprises 5 dimensions: 
mobility, self-care, usual activities, pain / discomfort, and anxiety / depression. Each 
dimension has 5 levels: no problems, slight problems, moderate problems, severe problems 
and extreme problems. The respondent is asked to indicate his / her health state by ticking (or 
placing a cross) in the box against the most appropriate statement in each of the 5 dimensions.
The EQ VAS records the respondent’s self-rated health on a vertical, visual analogue scale 
where the endpoints are labeled ‘the best health you can imagine’ and ‘the worst health you 
can imagine’. This information can be used as a quantitative measure of health outcome as 
judged by the individual respondents.
9.5
Pharmacokinetics / pharmacodynamics
It is planned to collect PK samples from all patients randomized. The data collected are 
intended to be used for PK analysis of the study population as a whole and should also give 
information about individual exposure to BAY 84-3174. Only the active metabolite BAY 84-
3174 will be measured from the plasma samples collected (see Section 7.2 for details 
regarding different BAY numbers). 
A sparse sampling scheme has been developed, which will allow for a limited number of PK 
samples to be obtained from each patient. The sampling time points have been included in the 
flow chart (see Table 9—1). The PK sampling schedule is detailed in the visit description 
(Section 9.2). It is important to exactly record in the patient’s file the time point when the PK 
sample is taken, as well as the times of the most recent medication intake prior to the blood 
sampling. The sampling variability will be used for modelling the PK and PD characteristics 
of the study medication.
Details about the collection, processing, storage and shipment of samples will be provided 
separately (e.g. sample handling sheets or laboratory manual).

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 48 of 85
9.6
Safety
Adverse events
9.6.1
9.6.1.1
Definitions
Definition of adverse event (AE)
In a clinical study, an AE is any untoward medical occurrence (i.e. any unfavorable and 
unintended sign [including abnormal laboratory findings], symptom or disease) in a patient or 
clinical investigation subject after providing written informed consent for participation in the 
study. Therefore, an AE may or may not be temporally or causally associated with the use of a 
medicinal (investigational) product.
A surgical procedure that was planned prior to the start of the study by any physician treating 
the patient should not be recorded as an AE (however, the condition for which the surgery is 
required may be an AE).
In the following differentiation between medical history and AEs, the term “condition” may 
include abnormal physical examination findings, symptoms, diseases, laboratory, or ECG 
findings.
Conditions that started before signing of informed consent and for which no 
symptoms or treatment are present until signing of informed consent are recorded as 
medical history (e.g. seasonal allergy without acute complaints).
Conditions that started before signing of informed consent and for which symptoms 
or treatment are present after signing of informed consent, at unchanged intensity, 
are recorded as medical history (e.g. allergic pollinosis).
Conditions that started or deteriorated after signing of informed consent will be 
documented as adverse events.
Definition of serious adverse event (SAE)
An SAE is classified as any untoward medical occurrence that, at any dose, meets any of the 
following criteria (a – f):
a.
Results in death
b. Is life-threatening
The term ‘life-threatening’ in the definition refers to an event in which the patient was 
at risk of death at the time of the event, it does not refer to an event which 
hypothetically might have caused death if it were more severe.
c.
Requires inpatient hospitalization or prolongation of existing hospitalization
A hospitalization or prolongation of hospitalization will not be regarded as an SAE if 
at least one of the following exceptions is met:
The admission results in a hospital stay of less than 12 hours
The admission is pre-planned 
(e.g. elective or scheduled surgery arranged prior to the start of the study; 
admission is part of the study procedures as described in Section 9.2)

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 49 of 85
The admission is not associated with an AE 
(e.g. social hospitalization for purposes of respite care).
However, it should be noted that invasive treatment during any hospitalization may 
fulfill the criterion of ‘medically important’ and as such may be reportable as an SAE 
dependent on clinical judgment. In addition, where local regulatory authorities 
specifically require a more stringent definition, the local regulation takes precedence.
d. Results in persistent or significant disability / incapacity
Disability means a substantial disruption of a person’s ability to conduct normal life’s 
functions.
e.
Is a congenital anomaly / birth defect
f.
Is another serious or important medical event as judged by the investigator
Definition of treatment-emergent adverse event
An AE is classified as treatment-emergent if it occurs or worsens after the first dose of study 
drug up to 6 weeks after the last dose of study drug.
9.6.1.2
Classifications for adverse event assessment
All AEs will be assessed and documented by the investigator according to the categories 
detailed below. 
9.6.1.2.1
Seriousness
For each AE, the seriousness must be determined according to the criteria given in 
Section 9.6.1.1.
9.6.1.2.2
Intensity
The intensity of an AE is classified according to the following categories:

Mild - usually transient in nature and generally not interfering with normal activities

Moderate - sufficiently discomforting to interfere with normal activities

Severe - prevents normal activities
9.6.1.2.3
Causal relationship 
The assessment of the causal relationship between an AE and the administration of treatment 
is a decision to be made by the investigator, who is a qualified physician, based on all 
information available at the time of the completion of the CRF.
The assessment is based on the question whether there was a “reasonable causal relationship” 
to the study treatment in question.
Possible answers are “yes” or “no”.
An assessment of “no” would include:
1.
The existence of a highly likely alternative explanation, e.g. mechanical bleeding at 
surgical site.
or

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 50 of 85
2.
Non-plausibility, e.g. the patient is struck by an automobile when there is no indication 
that the drug caused disorientation that may have caused the event; cancer developing a 
few days after the first drug administration.
An assessment of “yes” indicates that that the AE is reasonably associated with the use of the 
study treatment.
Factors to be considered in assessing the relationship of the AE to study treatment include:
The temporal sequence from drug administration: The event should occur after the drug is 
given. The length of time from drug exposure to event should be evaluated in the clinical 
context of the event.
Recovery on drug discontinuation (de-challenge), recurrence on drug re-introduction 
(re-challenge): Patient’s response after de-challenge or re-challenge should be considered 
in view of the usual clinical course of the event in question.
Underlying, concomitant, intercurrent diseases: 
Each event should be evaluated in the context of the natural history and course of the 
disease being treated and any other disease the patient may have.
Concomitant medication or treatment: 
The other drugs the patient is taking or the treatment the patient receives should be 
examined to determine whether any of them might have caused the event in question.
Known response pattern for this class of drug.
Exposure to physical and / or mental stresses: The exposure to stress might induce adverse 
changes in the recipient and provide a logical and better explanation for the event
The pharmacology and pharmacokinetics of the study treatment: 
The pharmacokinetic properties (absorption, distribution, metabolism and excretion) of 
the study treatment, coupled with the individual patient’s pharmacodynamics should be 
considered.
The assessment is not possible
Causal relationship to protocol-required procedure(s)
The assessment of a possible causal relationship between the AE and protocol-required 
procedure(s) is based on the question whether there was a “reasonable causal relationship” to 
protocol-required procedure(s).
Possible answers are “yes” or “no”.
9.6.1.2.4
Action taken with study treatment 
Any action on study treatment to resolve the AE is to be documented using the categories 
listed below.
Drug withdrawn
Drug interrupted
Dose not changed
Not applicable
Unknown

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 51 of 85
9.6.1.2.5
Other specific treatment(s) of adverse events
None
Remedial drug therapy
Other
9.6.1.2.6
Outcome
The outcome of the AE is to be documented as follows: 
Recovered / resolved
Recovering / resolving
Recovered / resolved with sequelae
Not recovered / not resolved
Fatal
Unknown
9.6.1.3
Assessments and documentation of adverse events
The investigator has to record on the respective CRF pages all adverse events occurring in the 
period between the signing of the informed consent and the end of the follow-up phase (Visit 
9); after the end of the follow-up phase there is no requirement to actively collect AEs 
including deaths. The type of information that should be assessed and recorded by the 
investigator for each AE is listed in Section 9.6.1.2. 
“Death” should not be recorded as an AE on the AE page. Instead, “death” is the outcome of 
an underlying AE(s).
For all serious adverse events (SAEs) the sponsor has to carry out a separate assessment for 
expectedness, seriousness and causal relationship to study drug.
9.6.1.4
Reporting of serious adverse events
The definition of serious adverse events (SAEs) is given in Section 9.6.1.1. Each SAE must 
be followed up until resolution or stabilization by submission of updated reports to the 
designated recipient.
If an SAE is unexpected, i.e. the event is not previously documented in the investigator’s 
brochure (IB) (new occurrence) and is suspected to be related to the study drug, this event is 
considered a Suspected Unexpected Serious Adverse Reaction (SUSAR). In general, SUSARs 
will be unblinded by the sponsor for regulatory reporting (see below for exceptions). 
Investigator’s notification of the sponsor
All investigators will be thoroughly instructed and trained on all relevant aspects of the 
investigator’s reporting obligations for SAEs. This information, including all relevant contact 
details, is summarized in the investigator site file. This information will be updated as needed.
The investigator must report immediately (within 24 hours of the investigator’s awareness) all 
SAEs occurring during the observation period defined in Section 9.6.1.3 to the recipient 

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 52 of 85
detailed in the instructions for SAE reporting included in the Investigator File. For this, an AE 
page and the complementary SAE pages in the CRF must be completed for each SAE.
SAEs occurring after the protocol-defined observation period will be processed by the 
sponsor according to all applicable regulations.
Notification of the IECs / IRBs
Notification of the IECs / IRBs about all relevant events (e.g. SAEs, SUSARs) will be 
performed by the sponsor and / or by the investigator according to all applicable regulations.
Notification of the authorities
The processing and reporting of all relevant events (e.g. SAEs, SUSARs) to the authorities 
will be done by the sponsor according to all applicable regulations.
Sponsor’s notification of the investigational site
The sponsor will inform all investigational sites about reported relevant events (e.g. SUSARs) 
according to all applicable regulations.
Protocol-specific exceptions to SAE unblinding / reporting
If reported as SUSARs, the following clinical events will be exempted from unblinding and 
expedited reporting by the sponsor to investigators, IECs / IRBs, and regulatory agencies, 
since they are considered, consistent with the underlying condition, as disease related in the 
defined study population:

CV death 

Worsening of heart failure

Non-fatal myocardial infarction

Non-fatal stroke

Transient ischemic attack

Cardiac arrhythmias

Coronary revascularization procedures.
Note that all of these events will be reviewed and monitored by an external DMC unblinded 
to treatment as part of the overall assessment of safety and efficacy for neladenoson bialanate. 
Based upon their regular review of unblinded safety results, the DMC is empowered to make 
recommendations with regard to trial conduct to assure the continuing appropriate safety of 
the subjects participating in the study.
9.6.1.5
Expected adverse events
For this study, the applicable reference document is the most current version of the 
investigator’s brochure (IB) for neladenoson bialanate.
Overview listings of frequent events that have occurred so far in the clinical development are 
shown in the current IB. If relevant new safety information is identified, the information will 
be integrated into an update of the IB and distributed to all participating sites.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 53 of 85
The expectedness of AEs will be determined by the sponsor according to the applicable 
reference document and according to all local regulations.
9.6.1.6
Adverse events of special interest
Adverse events of special interest have to be reported to the sponsor along the timelines set 
for serious adverse events (even though they may not be classified as serious), i.e. within 24 
hours of the investigator’s awareness, as described in section 9.6.1.4.
Adverse events of special interest are:

Symptomatic bradycardia (HR < 50 bpm)

Findings in ECG and / or AVIVO device as follows:
o
Mobitz type I AV-block leading to withdrawal or interruption of study drug
o
Mobitz type II AV block leading to withdrawal or interruption of study drug or 
leading to any change in therapy 
o
Third degree AV blocks
Pregnancies
9.6.2
Females of childbearing potential are excluded from the study. However, the investigator 
must report to the sponsor any pregnancy occurring in a female study patient during her 
participation in this study. The outcome of the pregnancy should be followed up carefully, 
and any outcome of the mother and the child at delivery should be reported.
The child’s health should be evaluated at birth.
For a pregnancy in the partner of a male study patient, all efforts will be made to obtain 
similar information on course and outcome, subject to the partner’s consent.
For all reports, the forms provided are to be used. The investigator should submit them within
the same timelines as an SAE. 
Further safety
9.6.3
9.6.3.1
Laboratory evaluations
All laboratory evaluations will be done by central laboratory. Additional re-tests for liver 
monitoring (Section 9.6.3.6) will be done locally.
Hematology: erythrocytes, hemoglobin, hematocrit, MCV, MCH, MCHC, reticulocytes, 
leukocytes, differential blood count, platelets
Clinical chemistry: aspartate aminotransferase (AST), alanine aminotransferase (ALT), 
alkaline phosphatase (AP), gamma glutamyl transpeptidase (GGT), lactate dehydrogenase 
(LDH), creatine kinase (CK), amylase, lipase, glucose, cholesterol (HDL, LDL, total), 
triglycerides, creatinine, urea, uric acid, bilirubin, total protein, albumin, sodium, potassium, 
calcium, chloride, magnesium, anorganic phosphate
Coagulation: partial thromboplastin time (PTT), international normalized ratio (INR)

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 54 of 85
9.6.3.2
Physical examination
The physical examination (by means of inspection, palpation, auscultation) will be performed 
by a physician at the investigational site covering at least the organs of the cardiovascular, 
respiratory, abdominal and neurological system. 
Abnormal physical examination findings are recorded either as medical history or as adverse 
events (see Section 9.6.1.1).
9.6.3.3
12-lead ECG
The standard 12-lead ECG will be evaluated by the investigator and the following parameters 
will be recorded in the eCRF: HR, PR interval, QRSD interval, QT interval (uncorrected). 
QTcB (QT interval frequency-corrected according to Bazett’s formula) will also be calculated 
but will not be valid for evaluation. The frequency-corrected QT interval will be calculated by 
data management according to the formulas of both Bazett and Fridericia. 
All ECGs recorded during the study will be evaluated by a physician. He / she will document 
the diagnosis(es) including an overall assessment of the findings and their clinical relevance. 
Any clinically relevant abnormality will be documented as an AE or SAE.
9.6.3.4
Blood pressure and heart rate
Heart rate and blood pressure (systolic and diastolic) will be measured by a member of the 
investigator’s study team with the patient at rest.
9.6.3.5
AVIVO monitoring
AVIVO Mobile Patient Management System will be used to monitor patients’ cardiovascular 
status as part of the safety assessment. The cardiac monitoring device will be worn as 
specified in Section 9.1. 
The system is intended to continuously measure, record and periodically transmit ECG data. 
The system can detect (but is not limited to) higher degree AV-blocks > I°, SVTs (e.g. atrial 
fibrillation [AF], atrial flutter, paroxysmal SVTs), ventricular ectopy, bradyarrhythmias, 
conduction disorders and heart rate variability. Included in the service is the monitoring center 
- an independent certified diagnostic testing center staffed with ECG-trained technicians who 
read through the transmitted events 24h/7d. An electrophysiologist is also on staff for 
interpretation of difficult rhythms. The system has achieved CE mark and has US FDA 
clearance. 
AF will be assessed as subclinical AF and AF burden as an exploratory endpoint. No patient
symptoms will be captured as part of this analysis, if not reported by the patient at routine 
visits. 
Apart from safety assessments, also the patient’s everyday physical activity (e.g. duration, 
intensity) will be tracked by the AVIVO device. This is part of the secondary efficacy 
variables. Details of the cardiac monitoring and the device to be worn by the patient will be 
outlined in a manual that will be provided to all participating centers. All collected variables 
will be described in the SAP.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 55 of 85
9.6.3.6
Liver function monitoring
Any patient with an ALT or AST > 3 x ULN or alkaline phosphatase (AP) > 2 x ULN must be 
re-tested as soon as possible but at the latest within 48-72 hours of the investigator becoming 
aware of the result. This re-testing and any subsequent testing based on elevated levels should 
include measurement of ALT, AST, total and direct bilirubin, and AP, and will be assessed by 
local laboratory. Every effort should be made to clarify the etiology of elevated levels. Patient 
management is at the discretion of the investigator but the treating physician may continue the 
study drug during retesting. Liver function test monitoring should be performed as above for 
all patients even if the study drug is interrupted until tested values have normalized or 
returned to patient’s baseline. If close liver monitoring is not possible then the patient should 
discontinue study medication.
For ALT or AST > 3 x ULN concurrent with a total bilirubin > 2 x ULN, every effort should
be made to clarify any possible underlying disease(s).
The frequency of liver function tests based on re-test values is shown in Table 9—3.
Table 9—3: Liver function monitoring 
ALT, AST or AP level
at re-test
Frequency
Further notice
ALT or AST > 3 x ULN 2-3 times a week
Obtain details on liver related symptoms and exclude 
other causes of liver enzyme elevations
ALT or AST ≤ 3 x ULN Once a week
Until return to normal or patient baseline levels
AP > 2 x ULN
2-3 times a week
Obtain details on liver related symptoms and exclude 
other causes of liver enzyme elevations
ALT = alanine aminotransferase; AP = alkaline phosphatase; AST = aspartate aminotransferase; ULN = upper 
limit of normal
Discontinuation of treatment should be considered if: 

ALT or AST > 8 x ULN 

ALT or AST > 5 x ULN for more than 2 weeks 

ALT or AST > 3 x ULN and (total bilirubin > 2 x ULN or INR > 1.5) 

ALT or AST > 3 x ULN with the appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and / or eosinophilia (> 5%) 

AP > 2 x ULN or ALT/AP < 2 for more than 2 weeks if other causes of cholestasis are 
excluded
9.7
Other procedures and variables
Not applicable.
9.8
Appropriateness of procedures / measurements
All parameters, as well as the methods to measure them, are standard variables / methods in 
clinical studies and / or clinical practice. They are widely used and generally recognized as 
reliable, accurate, and relevant.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 56 of 85
10.
Statistical methods and determination of sample size 
10.1
General considerations
Statistical analyses will be performed by or under the supervision of the sponsor’s study 
statistician and the assigned study statistical analyst using statistical analysis system (SAS); 
the version used will be specified in the SAP. 
A general description of the statistical methods to be used to analyze efficacy and safety in 
this is study is outlined below. A detailed SAP will be provided as a separate document that 
will be finalized and approved before database lock. The SAP will accommodate protocol 
amendments or unexpected issues in study execution or data that affect planned analyses and 
will provide more details on the analytical approaches, output tables and figures.
A meta-analysis of this study (17582) and of the study 15128 in patients with HFrEF, which 
is conducted at the same time, will be specified in a separate SAP.
10.2
Analysis sets
Documentation of protocol deviations and assignment of patients to analysis sets will be 
performed according to the sponsor’s applicable Standard Operating Procedures and / or 
Operation Instructions.
The primary efficacy variable will be analyzed using the per-protocol set (PPS) and the full 
analysis set (FAS) for sensitivity analyses. 
Data for all patients who signed informed consent but were not randomized will not be 
included in any statistical analyses except standard disposition tables and listings provided in 
the clinical study report (Screening failures and discontinued patients). 
The statistical analysis sets are defined as follows:
Full analysis set (FAS)
The FAS population consists of all randomized unique patients. According to the ICH E9 
guideline, this analysis set is as complete as possible and as close as possible to the intent-to-
treat (ITT) ideal. Patients will be analyzed as randomized. The FAS will be used to display 
baseline characteristics and to display efficacy analyses.
Safety analysis set (SAF)
The SAF population consists of all randomized patients who received at least one dose of 
study medication after randomization. The SAF will be used to display safety analyses. For 
safety analyses, patients will be analyzed as treated.
Per-protocol set (PPS)
The PPS population consists of all FAS population patients without validity findings. Validity 
findings may include adherence and compliance issues and the violation of 
inclusion / exclusion criteria affecting efficacy evaluation.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 57 of 85
A list of potential validity findings will be provided in a separate protocol deviation document
which will be finalized before database lock. The detailed definitions and the assignment of 
patients to this analysis set will be based on the validity review meeting. Patients will be 
analyzed as treated.
Pharmacokinetic analysis set (PKS)
The PKS population consists of all patients treated with neladenoson bialanate with at least 
1 valid BAY 84-3174 plasma concentration and without protocol deviation that would 
interfere with the evaluation of the PK data.
10.3
Variables and planned statistical analyses
Variables
10.3.1
10.3.1.1
Primary efficacy variable

Absolute change from baseline in 6MWD after 20 weeks of treatment
10.3.1.2
Secondary efficacy variables
Secondary efficacy variables across different domains are: 

Activity (e.g. duration, intensity) reported values and absolute change from baseline at 
20 weeks

NT-proBNP (pg/mL), measured values (log transformed) and absolute / relative 
change from baseline at 20 weeks to assess elevated filling pressures

High sensitivity troponin T (hs-TNT; ng/L), measured values (log transformed) and 
absolute / relative change from baseline at 20 weeks as a biomarker of myocardial 
injury

KCCQ, as described in Section 9.4.6.1, measured values and absolute / relative change 
from baseline
10.3.1.3
Other exploratory variables

Echocardiographic parameters, as described in Section 9.4.3, measured values and 
absolute / relative change from baseline at 20 weeks

Mandatory biomarkers, as described in Section 9.4.4, measured values and 
absolute / relative change from baseline at 20 weeks, including UACR, cystatin-C, 
NGAL for the evaluation of kidney function 

CV mortality, HF hospitalization and urgent visits for HF as clinical outcomes

All-cause mortality, non-fatal myocardial infarction, non-fatal stroke

EQ-5D QoL, as described in 9.4.6.2, measured values and absolute / relative change 
from baseline

Change in NYHA class

Absolute change in score on Borg CR 10 Scale

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 58 of 85
10.3.1.4
Safety variables
Safety and tolerability variables are:

Adverse events (Section 9.6.1), including
o
SAEs, AEs, treatment-emergent AEs and AEs of special interest, including AV 
blocks > I°
o
SAEs and AEs leading to discontinuation of interruption of study drug, 
including AV blocks in particular

Laboratory abnormalities (Section 9.6.3.1), measured values and change from 
baseline, in particular
o
Change in renal function measured by eGFR change from baseline
o
Change in liver function measured by bilirubin (total and fractions), AST and 
ALT from baseline

12-ECG abnormalities (Section 9.6.3.3) and PR interval duration

Blood pressure and heart rate (Section 9.6.3.4); measured values and change from 
baseline

Number of clinically significant findings in ECG and / or AVIVO device report
Statistical and analytical plans 
10.3.2
All data will be listed and all variables will be summarized by means of descriptive statistics 
according to their type.
Summaries by treatment group using appropriate descriptive statistics will be provided for all 
study variables including demographic and baseline characteristics. Summary statistics will be 
presented for the original data as well as for the difference to baseline. Descriptive statistics 
such as mean, median, standard deviation, quantiles, minimum, and maximum will be used to 
summarize continuous variables. Counts and percentages will be used to summarize 
categorical variables. Life tables and Kaplan-Meier estimates will be used to summarize time-
to-event variables. Graphical data displays may also be used to summarize the data. 
Confidence intervals will be provided at a 2-sided level of 90% unless otherwise stated.
For this combined proof-of-concept and dose-finding study, an overall one-sided type I error 
level of 5% is planned to be used. The type I error will be controlled for the primary analysis 
of the primary variable.
There will be no formal control of the type I error for secondary or explorative analyses of the 
primary variables and any analysis of other efficacy variables.
10.3.2.1
Subgroups
In order to assess the homogeneity of the dose response across the most important prognostic 
and predictive factors, subgroup analyses will be performed. 

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 59 of 85
‘Key’ subgroups comprise: 

LVEF(%) at baseline: < 55 vs. ≥55

NT-proBNP (pg/ml) at baseline: ≤ median vs. > median

NYHA class at baseline: II vs. III / IV

Prior ß-blocker: yes vs. no
Truly exploratory analyses, i.e., mainly summary statistics, will be provided for a spectrum of 
demographic, disease and clinical characteristics, including

Age (years): < 65, 65-75, > 75 

Gender: male vs. female

Race: White vs. non-white

Region: North America / South America / West Europe / East Europe / Asia

Region: Japan vs. rest-of-the-world (analysis to be included in reports specific for 
Japan only) 

BMI at baseline (kg/m²): ≤30 vs. > 30

Time of CHF diagnosis to randomization (months): ≤3 vs. > 3

Prior hospitalization for heart failure: yes vs. no

Etiology of CHF: ischemic vs. non-ischemic

Diabetes: yes vs. no

Atrial fibrillation: yes vs. no

Hypertension: yes vs. no

Prior medication:
o
Prior ß-blocker in max tolerated dose: yes vs. no
o
Prior use of aldosterone antagonist: yes vs. no
o
Prior use of ACE inhibitor: yes vs. no
o
Prior use of ARB: yes vs. no

Estimated GFR (ml/min/1.73 m2): ≤60 vs. > 60
Further details will be described in detail in the SAP. 
10.3.2.2
Analysis of the primary efficacy variable
It is planned to perform a test for a dose-response signal under the assumption of a nearly 
monotone dose-response relationship in the dose range considered. The MCP-Mod method 
(84) combining multiple comparison procedures (MCP) principles with modeling techniques 
will be used for the primary statistical analysis of the primary efficacy variable. This method 
allows the flexibility of modeling for dose estimation, while preserving the robustness to 
model misspecification associated with MCP procedures.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 60 of 85
Assumptions
Five active doses of neladenoson bialanate will be used in this study: 5 mg, 10 mg, 20 mg, 
30 mg, and 40 mg, as well as a placebo arm corresponding to a 0 mg dose. 
The measurements of the primary efficacy variable are assumed to be normally distributed 
with the same standard deviation σ and independent between patients.
The following assumptions were made for the absolute change from baseline in 6MWD over 
20 weeks:

the expected mean effect under the placebo dose is assumed as an absolute difference 
from baseline of = 0 m with a standard deviation of = 80 m

while the maximum observable mean effect under neladenoson bialanate within the 
dose range considered is assumed as an absolute increase of = 40 m with a standard 
deviation of = 80 m.
This results in an expected maximum effect size of (40-0)/80 = 0.5.
It is assumed that the primary efficacy variable, denoted as , is observed for the 6 parallel 
groups corresponding to doses levels: (placebo =) 1 < 2 < … < k, where k = 6.
For patient j within treatment group i the response can then be described by the following 
model:
 = 	(, ) + ,       ~(0, ),       = 1, … , ,    = 1,  … ,  ,  
where 	(. ) is parameterized by a vector of parameters  and  is the error term.
A candidate set with M=5 different dose response shapes 	(. ) based on four models was 
chosen for the MCP-Mod method. Table 10—1 displays the response expressions for the 
shapes in the candidate set. Figure 10—1 shows the corresponding dose-response shapes. The 
model parameters were obtained through discussions with experts in the clinical team, taking 
prior beliefs and uncertainty into account.
Table 10—1: Dose-response shapes used in the candidate set
Model
Response as function of dose d
Linear
d
Sigmoidal Emax 1
40.1 d4 / (94 + d4)
Sigmoidal Emax 2
45 d3 / (203 + d3)
Emax
41.25 d / (1.25 + d)
Quadratic
2.667 d – 0.044 d²

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 61 of 85
Figure 10—1: Dose-response shapes used in the candidate set
Based on the standardized versions of the models in the candidate set and the sample size 
allocation planned for this study, the optimum contrast coefficients for the 5 contrast tests on 
the dose-response shapes can be derived.
Analysis
Step 1: Detection of dose-response signal
For detecting an overall trend, or a dose-response signal, each of the M=5 dose-response 
shapes in the candidate set will be tested, using a single contrast test based on the updated 
version of contrast coefficients taking the actual sample sizes per treatment group into 
account.
For each model m, m = 1, …, 5, in the candidate set 
the null hypothesis
:  !
 = 0
will be tested against 
the respective 1-sided alternative hypothesis
":  !
 > 0, 
where !
 = (!"
 , … , !$
 )% = (	
(", 
 ), … , 	
($, 
 ))′ and
	 is the standardized version of the dose-response model 	(, ) = ' + '"	(, ). In 
this parameterization, ' is a location parameter and '" is a scale parameter such that only 
 determines the shape of the model function. 
A “proof-of-concept” dose-response relationship is detected if at least one single contrast test, 
is statistically significant, while controlling the family-wise error rate at level .
This analysis will be performed for the FAS and PPS populations, where the PPS analysis is 
the primary analysis. 

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 62 of 85
If no candidate model is statistically significant, the procedure stops, indicating that a dose-
response relationship cannot be established from the observed data.
Out of the statistically significant models in the candidate set a best model can be selected for 
the next step: modeling and estimation. 
Step 2: Modeling and estimation of target doses
If a dose-response signal is established, the selected dose-response model(s) will be fitted to 
the observed data to estimate the model parameters. 
The estimated dose-response model will be plotted against the doses including 90% 
confidence bands. Once the dose-response model has been successfully fitted to the data, 
target dose(s) of interest are estimated. Given a clinically relevant effect ∆ , a minimum 
effective dose ()*+∆) associated with model 	(, ) is defined as
)*+∆= argmin2∈(24,25]{	(, ) ≥	(", ) + ∆}.
Estimates of )*+∆will be calculated for a clinically relevant change in 6MWD assumed as 
∆ = 40 m and potentially a plausible range of ∆values which will be defined in the SAP.  In 
addition, estimates considering confidence bounds for the predicted value at a certain dose 
may be used. The final choice of the target dose depends on the evaluation of the primary 
efficacy variable and other efficacy variables, as well as safety considerations.
Modeling and estimation will be performed for the FAS and PPS populations as well as for 
relevant subgroups.
Further details will be described in the SAP.
As a secondary analysis pairwise comparisons of the active neladenoson bialanate dose 
groups with the placebo group will be performed without controlling the family-wise error 
rate.
10.3.2.3
Analysis of the secondary efficacy variables
The primary analysis of secondary efficacy variables will be performed in PPS, sensitivity 
analyses might be performed in the FAS. The secondary efficacy variables will be analyzed 
using similar statistical methods as for the primary efficacy variable, i.e. the MCP-Mod 
method with the same standardized candidate dose-response shapes and corresponding 
coefficients as for the primary variable. In addition to analyses comparing population means 
in the different dose groups, the number of patients in whom the individual change from 
baseline value crossed clinically meaningful thresholds will be analyzed. The totality of 
evidence for the primary and secondary efficacy variables will be combined and used to 
assess the drug effect over dose levels. 
All other efficacy variables will be analyzed descriptively. 
Further details will be described in the SAP.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 63 of 85
10.3.2.4
Analysis of the safety variables
If not indicated otherwise, evaluation of safety variables will be done using the SAF.
Adverse events
The adverse events (AE) analysis will be performed as treated in the SAF. All tabulations will 
be descriptive only.
Individual listings of AEs will be provided. The incidence of treatment-emergent AEs and 
drug-related (treatment-emergent) AEs will be tabulated by treatment group using MedDRA 
terms. Separate tables and listing for serious AEs and death will be provided. 
Further safety parameters
The safety evaluation of laboratory data will include:

Descriptive analysis of continuous laboratory parameters, and their changes from 
baseline by visit and treatment group.

Incidence rates of treatment-emergent laboratory values outside of normal range by 
treatment group.

Listings of laboratory data out of normal range.
Vital signs and their changes from baseline will be analyzed descriptively by visit and by 
treatment group.
ECG-findings (like AV-conduction abnormalities) will be summarized in frequency tables. A 
table displaying the number of patients with AV-block > I° will be provided.
Data from the AVIVO monitoring will be summarized; details will be described in the SAP.
Summary statistics and figures of heart rate and blood pressure (systolic, diastolic, and mean 
arterial pressure) will be created.
10.3.2.5
Pharmacokinetic analyses
Pharmacokinetic analyses will be performed on the population valid for pharmacokinetics.
For the investigation of systemic exposure to BAY 84-3174 and its relationship with 
treatment effects, the plasma concentrations of BAY 84-3174 will be determined at different 
time points using a sparse sampling approach in all participating patients (see Section 9.5).
The plasma concentration vs. time data will be evaluated descriptively separated by dose and 
visit. Plots will be prepared pooling all individual plasma concentrations (naive pooling) vs. 
actual relative study times (time of sample collection after time of study drug administration).
Furthermore, the pharmacokinetic data and the relationship of markers of BAY 84-3174 
exposure (e.g. Cmax, AUC) with treatment effects will be evaluated using non-linear mixed 
effect modeling (NONMEM). The latter evaluation will be described in a separate analysis 
plan and will be reported under separate cover.
The PK bioanalysis will be performed under the responsibility of the Sponsor’s Bioanalytics 
Laboratory.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 64 of 85
10.3.2.6
Biomarker analyses
Biomarker data will be described by the following summary statistics: arithmetic mean, 
standard deviation, median, quantiles, minimum, and maximum.
Graphical displays of individual data as well as mean values with standard deviation will be 
included.
Missing data, censoring due to death, and drop outs 
10.3.3
Generally, missing data will be handled as such, i.e., no imputation of missing data will be 
performed. An exception is the analysis of the primary and secondary efficacy variables, as 
described below, and the timing of events relative to other events. For this purpose, data rules 
for the handling of missing or incomplete dates will be described in the SAP.
All missing or partial data will be presented in the patient data listing as they are recorded in 
the eCRF. 
A number of descriptive analyses will be performed to better understand missing data 
patterns. The frequency, proportion and the reasons for premature discontinuation of both the 
study and study treatment will be reported. Kaplan-Meier plots for “time to end of study 
treatment (calculated as days from first dose to the earliest date of last dose, including 
premature stop of study medication, and death)” and “time to end of study” will be provided, 
by treatment group and overall. 
The number of patients who prematurely discontinue study participation or intake of study 
medication will be carefully evaluated with respect to the key baseline characteristics, which 
will be further specified in the SAP, and the reasons for premature discontinuation of study 
and / or study treatment. If the proportion of patients who withdraw across the dose groups is 
not fairly balanced, the impact on the primary variable will be further explored. To further 
explore the missingness pattern with regards to the “missing at random” assumption, the mean 
of the baseline values of the efficacy variable will be summarized for patients with and 
without post-baseline observations, by treatment group and overall. 
For the analysis of the primary and secondary variables, it cannot necessarily be assumed that 
data are missing at random. As the choice of primary analysis will be based on assumptions 
that cannot be verified, the robustness of the results of the primary analysis will be 
investigated through appropriate sensitivity analyses making different assumptions, in 
accordance with the EMA “Guideline on missing data in confirmatory clinical trials”.
Efficacy analysis using the PPS
The primary efficacy analysis aims at evaluating the dose-response relationship of the primary 
and secondary efficacy variables for all randomized patients, who have remained in the study
and adhered to study treatment according to the study protocol until Week 20 (“completers 
and treatment adherers” analysis). Therefore, the primary analysis will be performed in the
per protocol set, a subset of the FAS comprising “compliant and adherent” patients (as much 
as possible, defined via validity criteria). To avoid bias, the PPS will also include those 
“compliant and adherent” patients who are “censored” due to CV death or a hospitalization 
for HF preventing the assessment of the relevant efficacy endpoints 20 weeks after 
randomization, to take place as planned. It is expected, that these are the only patients for 

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 65 of 85
whom missing observations need to be considered in the primary analysis. A “worst case”
approach will be used, where the missing change from baseline value will be imputed with a 
multiple of the worst change from baseline value, which is possible given the individual 
baseline value observed in the respective treatment group, or 0 if the worst change in that 
treatment group is positive. 
As a sensitivity analysis, a “completers and treatment adherers” only analysis excluding the 
censored patients in the per protocol analysis set will be performed. This strategy leads to 
unbiased estimates only if missing values are “missing completely at random” (MCAR), i.e. 
the missingness – including missing data due to death – is independent of both observed and 
unobserved outcomes. This condition is unlikely to hold exactly but rather approximately.
Further sensitivity analyses on the PPS may be performed if the missing data patterns suggest 
further exploration.
Efficacy analysis using the FAS
The efficacy analysis in the FAS aims at evaluating the dose-response relationship of the 
primary and secondary efficacy variables for all randomized patients. Efficacy analyses in the 
FAS will include the following:

Generally, it will be assumed that missing observations for the respective efficacy 
variables are missing at random. This implies that the behavior of the post dropout 
observations can be predicted from the observed variables using appropriate 
imputation models. Likely exceptions to the missing at random assumption are 
observations which are missing due to a patient’s CV death or HF hospitalization prior 
to the visit in Week 20. These observations can be assumed to be missing not at 
random (MNAR), i.e., that missingness depends both on observed and unobserved 
outcomes and that an explicit model for the patient’s statistical behavior after drop-out 
(or death) is required. Therefore, an analysis based on a pattern mixture framework 
(85) with different imputation rules depending on the reason for missingness will be 
used using a multiple imputation model, followed by a modification of the imputed 
data applying penalties: 
1. First, multiple imputation will be applied to draw sets of completed data, using an 
appropriate imputation model. Baseline characteristics which should be considered 
in the imputation model include but are not restricted to the baseline values of the 
respective efficacy variable, the treatment group, and sex. 
2. The imputed data will be modified by applying penalties. The choice of the penalty 
may be guided by the worst observed change from baseline for the respective 
outcome in the corresponding treatment group, e.g. by choosing the penalty as a 
multiple of the worst observed change from baseline value. 
3. After modifying the completed data sets, the primary analysis using the MCP-step 
of the MCP-Mod methodology will be applied to the multiply imputed datasets 
and the results will be combined. 

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 66 of 85

An analysis where for each patient without an observation at the visit in Week 20 the 
missing value will be imputed according to a last observation carried forward 
approach, including the baseline value. Such an analysis is usually biased but will 
make use of the observations obtained at early EOT visits.
For reproducibility, the SAS seed number for creating the random numbers for the multiple 
imputation will be set to the study number. More details will be described in the SAP.
10.4
Determination of sample size
This combined proof-of-concept and Phase IIb dose-finding study has been powered for the 
detection of a dose response signal in the primary efficacy variable. 
The sample size for the primary efficacy variable was evaluated under the assumptions 
described in Section 10.3.2.2 and a type I error level = 5% with the aim to achieve at least 
80% power for the one-sided primary multiple contrast test. The overall randomization ratio 
was assumed to be 3:1:2:2:2:2 for doses 0, 5, 10, 20, 30, and 40 mg.
Table 10—2 displays the power for the multiple contrast test in the MCP-Mod approach, used 
as primary analysis, for the set of specified alternatives.
Table 10—2: Power for multiple contrast test for set of different alternatives
Sample size
Power for alternative based on respective dose-response model (in %)
Overall
Per group a
Linear
Sigmoidal Emax 1
Sigmoidal Emax 2
Emax
Quadratic
Minimum
180
30
74.10
86.84
81.84
82.96
80.59
74.10
192
32
76.54
88.75
84.07
85.11
82.82
76.54
204
34
78.83
90.39
86.05
87.04
84.86
78.83
216
36
80.84
91.81
87.80
88.72
86.61
80.84
228
38
82.76
93.03
89.36
90.23
88.23
82.76
240
40
84.48
94.05
90.73
91.51
89.62
84.48
252
42
86.06
94.97
91.92
92.67
90.88
86.06
264
44
87.45
95.72
92.96
93.65
91.96
87.45
a Number of patients randomized to dose levels 10 mg, 20 mg, 30 mg, and 40 mg of neladenoson bialanate, 
for placebo sample size per group to be multiplied by 3/2, for dose level 5.0 mg sample size per group to be 
divided by 2.
To achieve at least 80% power for the multiple contrast test in the MCP-Mod approach under 
all different alternatives, a minimum of 36 patients per treatment group (54 patients for the 
placebo and 18 patients for the 5 mg group) is needed, resulting in an overall sample size of 
216 patients.
Based on this estimation, a total of 288 patients are planned to be randomized to the 
6 treatment groups:

72 patients are planned to be randomized to placebo (0 mg), 

48 patients each are planned to be randomized to the dose levels 10 mg, 20 mg, 30 mg, 
and 40 mg of neladenoson bialanate, and 

24 patients are planned to be randomized to the dose level 5 mg of neladenoson 
bialanate.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 67 of 85
These numbers already include adequate assumptions on expected drop-out after 
randomization and invalid or missing data. In the selected population it is expected that only 
about 75% of all randomized patients, i.e. about 216 patients, will contribute complete data to 
the primary analysis in the PPS. 
All power estimations and simulations were performed with the DoseFinding package in R, 
version 3.2.3 (2015-12-10).
10.5
Planned interim analyses
A formal interim analysis is not planned. Periodic data review by a DMC will be performed to 
monitor safety.
11.
Data handling and quality assurance
11.1
Data recording
The data collection tool for this study will be a validated electronic data capture system called 
RAVE. Patient data necessary for analysis and reporting will be entered / transmitted into a 
validated database or data system (e.g. TOSCA, SAS). 
Data required according to this protocol will be recorded by investigational site personnel via 
data entry into the internet based EDC software system RAVE, which Bayer has licensed 
from Medidata Solutions Worldwide. RAVE has been validated by Medidata Solutions 
Worldwide and Bayer for use in its clinical studies. RAVE allows for the application of 
software logic to set-up data entry screens and data checks to ensure the completeness and 
accuracy of the data entered by the site personnel. Bayer extensively applies the logic to 
ensure data are complete and reflect the clinical data requirements of the study. Data queries 
resulting from the application of the software logic are resolved by the site personnel. The 
data are stored at a secure host facility maintained by Medidata Solutions Worldwide and 
transferred on a periodic basis to Bayer's internal computer system via a secure Virtual Private 
Network.
All access to the RAVE system is through a password-protected security system that is part of 
the RAVE software. All internal Bayer and external investigator site personnel seeking access 
must go through a thorough RAVE training process before they are granted access to RAVE 
for use in Bayer's clinical studies. Training records are maintained.
All personnel with access to the RAVE system are supported by a Service Desk staffed with 
trained personnel to answer questions and ensure access is maintained such that data entry can 
proceed in a timely manner.
The RAVE System contains a system-generated audit trail that captures any changes made to 
a data field, including who made the change, why the change was made and the date and time 
it was made. This information is available both at the investigator’s site and at Bayer. Data 
entries made in the RAVE EDC screens are supported by source documents maintained for all 
patients enrolled in this study.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 68 of 85
Source documentation
The site must implement processes to ensure availability of all required source 
documentation. A source document checklist (not part of this protocol) will be used at the site 
to identify the source data for key data points collected and the monitor will work with the site 
to complete this.
It is the expectation of the sponsor that all data entered into the CRF has source 
documentation available at the site. 
Data recorded from screening failures
At minimum, the following data should be recorded in the CRF:
Demographic information (patient number; year of birth / age; sex; if permitted locally,
race / ethnicity)
Date of informed consent
Inclusion / exclusion criteria
Reason for premature discontinuation
o
AE information, if applicable
Date of last visit. 
These data will be transferred to the respective database.
For screening failures with an SAE, the following data should be collected in the CRF in 
addition to the data specified above:
All information related to the SAE such as: 
-
The SAE itself
-
Concomitant medication
-
Medical history
-
Other information needed for SAE complementary page
11.2
Monitoring
In accordance with applicable regulations, GCP, and sponsor’s / CRO’s procedures, monitors 
will contact the site prior to the start of the study to review with the site staff the protocol, 
study requirements, and their responsibilities to satisfy regulatory, ethical, and sponsor’s 
requirements. When reviewing data collection procedures, the discussion will also include 
identification and documentation of source data items.
The sponsor / designee will monitor the site activity to verify that the:
Data are authentic, accurate and complete. 
Supporting data may be requested (example: blood glucose readings to support a 
diagnosis of diabetes). 
Safety and rights of patients are being protected
Study is conducted in accordance with the currently approved protocol 
(including study treatment being used in accordance with the protocol)
Any other study agreements, GCP, and all applicable regulatory requirements are met.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 69 of 85
The investigator and the head of the medical institution (where applicable) agrees to allow the 
monitor direct access to all relevant documents.
11.3
Data processing
Data will be collected as described in Section 11.1. Clinical data management will be 
performed in accordance with sponsor’s applicable standards and data cleaning procedures. 
This is applicable for data recorded in the eCRF as well as for data from other sources (e.g. 
IxRS, laboratory, ECG, AVIVO).
For data coding (e.g. AEs, medication), internationally recognized and accepted dictionaries 
will be used.
After its initial release for biometrical analysis, the clinical database is planned to be re-
opened for the inclusion of the following additional data: pharmacokinetic data and biomarker 
data. 
11.4
Missing data 
The following measures will be implemented to minimize the amount of missing data.

Encourage further participation in the study, i.e. phone call 26 weeks after the start of 
treatment, even if the study medication is discontinued early. 

If the patient does not attend the visits in person, the investigator should make every effort 
to collect information on mortality and / or hospitalization from other sources, e.g. 
family / friend / general physician / etc.

Ask sites to call patients the day before certain study visits to remind them to remember 
the time they take their study medication and to remind them in case study medication 
should not be taken at home the next day.

Educate patients on the AVIVO device and train sites to prepare the patient’s skin for 
adherence of the sensor. Ask sites to call patients at the end of the wearing period to 
provide instructions for removal, storage and return at the next visit.

Try to avoid unnecessary patient withdrawals (see Section 6.4).
11.5
Audit and inspection
To ensure compliance with GCP and regulatory requirements, a member of the sponsor’s (or a 
designated CRO’s) quality assurance unit may arrange to conduct an audit to assess the 
performance of the study at the study site and of the study documents originating there. The 
investigator / institution will be informed of the audit outcome.
In addition, inspections by regulatory health authority representatives and IEC(s)  / IRB(s) are 
possible. The investigator should notify the sponsor immediately of any such inspection.
The investigator / institution agrees to allow the auditor or inspector direct access to all 
relevant documents and allocate his / her time and the time of his / her staff to the 
auditor / inspector to discuss findings and any issues. Audits and inspections may occur at any 
time during or after completion of the study.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 70 of 85
11.6
Archiving
Essential documents shall be archived safely and securely in such a way that ensures that they 
are readily available upon authorities’ request.
Patient (hospital) files will be archived according to local regulations and in accordance with 
the maximum period of time permitted by the hospital, institution or private practice. Where 
the archiving procedures do not meet the minimum timelines required by the sponsor
(minimum is 25 years; longer if required by local regulation), alternative arrangements must 
be made to ensure the availability of the source documents for the required period.
The investigator / institution notifies the sponsor if the archival arrangements change (e.g. 
relocation or transfer of ownership).
The investigator site file is not to be destroyed without the sponsor’s approval.
The contract with the investigator / institution will contain reference to all regulations relevant 
for the study center.
12.
Premature termination of the study
The sponsor has the right to close this study (or, if applicable, individual segments thereof 
[e.g. treatment arms; dose steps; centers]) at any time, which may be due but not limited to the 
following reasons: 
If risk-benefit ratio becomes unacceptable owing to, for example,
Safety findings from this study (e.g. SAEs)
Results of parallel clinical studies
Results of parallel animal studies 
(on e.g. toxicity, teratogenicity, carcinogenicity or reproduction toxicity).
If the study conduct (e.g. recruitment rate; drop-out rate; data quality; protocol 
compliance) does not suggest a proper completion of the trial within a reasonable time 
frame.
The investigator has the right to close his / her center at any time.
For any of the above closures, the following applies:
Closures should occur only after consultation between involved parties. Final decision 
on the closure must be in writing.
All affected institutions (e.g. IEC(s) / IRB(s); competent authority(ies); study center; 
head of study center) must be informed as applicable according to local law.
All study materials (except documentation that has to remain stored at site) must be 
returned to the sponsor. The investigator will retain all other documents until 
notification is given by the sponsor for destruction.
In the event of a partial study closure, ongoing patients, including those in post study 
follow-up, must be taken care of in an ethical manner.
Details for individual patient's withdrawal can be found in Section 6.4.1.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 71 of 85
13.
Ethical and legal aspects
13.1
Investigator(s) and other study personnel
Sponsor’s study medical expert is identified on the Title page.
Coordinating investigators in this study will be:
 USA
Tel. 
Fax 
E-mail: 
 USA
Tel. 
Fax 
E-mail: 
All other study personnel not included in this section are identified in a separate personnel list 
(not part of this clinical study protocol) as appropriate. This list will be updated as needed; an 
abbreviated version with personnel relevant for the centers will be available in each center’s 
investigator site file.
Whenever the term ‘investigator’ is noted in the protocol text, it may refer to either the 
principal investigator at the site, or an appropriately qualified, trained and delegated 
individual of the investigational site.
The principal investigator of each center must sign the protocol signature page and must 
receive all required external approvals (e.g. health authority, ethics committee, sponsor) 
before patient recruitment may start at the respective center. Likewise, all amendments to the 
protocol must be signed by the principal investigator and must receive all required external 
approvals before coming into effect at the respective center.
A complete list of all participating centers and their investigators, as well as all required 
signature documents, will be maintained in the sponsor’s study file.
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 72 of 85
The global sponsor of this study is identified on the title page of this protocol. If required by 
local law, local co-sponsors will be nominated; they will be identified on the respective 
country-specific signature pages.
External data evaluation bodies
Steering Committee
The main task of the Steering Committee, which is composed of a panel of experts in the 
field, is to support the conduct of the study and to advise the sponsor on clinical, medical, and 
scientific questions. Details of the committee will be specified in the Steering Committee 
charter.
Data Monitoring Committee 
Ongoing safety monitoring during the conduct of the study will be performed by an external 
and unblinded DMC. Analysis periods and procedures will be defined in an operational 
charter (DMC Charter) filed in the study file. Following data review, the DMC will provide 
written recommendations that will be transferred to Bayer. All other definitions will be 
provided in the DMC charter.
Clinical Events Committee
Blinded adjudication of all HF hospitalizations, urgent visits for HF and deaths will be 
performed by a central CEC as described in the CEC charter. Data entry procedures and 
documentation necessary for case adjudication will also be described in the CEC charter. 
Adjudication results will be the basis for the final analysis.
13.2
Funding and financial disclosure
Funding
This study will be funded by its sponsor.
Financial disclosure 
Each investigator (including principal and / or any sub investigators) who is directly involved 
in the treatment or evaluation of research patients has to provide a financial disclosure 
according to all applicable legal requirements. All relevant documentation will be filed in the 
trial master file.
13.3
Ethical and legal conduct of the study
The procedures set out in this protocol, pertaining to the conduct, evaluation, and 
documentation of this study, are designed to ensure that the sponsor and investigator abide by 
Good Clinical Practice (GCP) guidelines and the guiding principles detailed in the 
Declaration of Helsinki. The study will also be carried out in keeping with applicable local 
law(s) and regulation(s).
Documented approval from appropriate IEC(s) / IRBs will be obtained for all participating 
centers / countries before start of the study, according to GCP, local laws, regulations and 
organizations. When necessary, an extension, amendment or renewal of the IEC / IRB 

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 73 of 85
approval must be obtained and also forwarded to the sponsor. The responsible unit (e.g. 
IEC / IRB, head of the study center / medical institution) must supply to the sponsor, upon 
request, a list of the EC / IRB members involved in the vote and a statement to confirm that 
the IEC / IRB is organized and operates according to GCP and applicable laws and 
regulations.
Strict adherence to all specifications laid down in this protocol is required for all aspects of 
study conduct; the investigator may not modify or alter the procedures described in this 
protocol. 
Modifications to the study protocol will not be implemented by either the sponsor or the 
investigator without agreement by both parties. However, the investigator or the sponsor may 
implement a deviation from, or a change of, the protocol to eliminate an immediate hazard(s) 
to the trial subjects without prior IEC / IRB / sponsor approval / favorable opinion. As soon as 
possible, the implemented deviation or change, the reasons for it and if appropriate the 
proposed protocol amendment should be submitted to the IEC / IRB / head of medical 
institution / sponsor. Any deviations from the protocol must be explained and documented by 
the investigator.
Details on discontinuation of the entire study or parts thereof can be found in Section 12.
13.4
Patient information and consent
All relevant information on the study will be summarized in an integrated patient information 
sheet and informed consent form provided by the sponsor or the study center. A sample 
patient information and informed consent form is provided as a document separate to this 
protocol.
Based on this patient information sheet, the investigator or designee will explain all relevant 
aspects of the study to each patient prior to his / her entry into the study (i.e. before any 
examinations and procedures associated with the selection for the study are performed or any 
study-specific data is recorded on study-specific forms).
The investigator will also mention that written approval of the IRB / IEC has been obtained.
Each patient will be informed about the following aspects of premature withdrawal:
Each patient has the right to withdraw from the study at any time without any 
disadvantage and without having to provide reasons for this decision.
The patient’s consent covers end-of-study examinations as specified in the visit 
description described in Section 9.2 to be conducted after withdrawal of consent to 
treatment.
The patient’s data that have been collected until the time of withdrawal will be retained 
and statistically analyzed in accordance with the statistical analysis plan. 
Patient-specific data on the basis of material obtained before withdrawal may be 
generated after withdrawal (e.g. image reading, analysis of biological specimen such as 
blood, urine or tissues); these data would also be retained and statistically analyzed in 
accordance with the statistical analysis plan. The patient has the right to object to the 
generation and processing of this post-withdrawal data. The patient’s oral objection may 
be documented in the patient’s source data.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 74 of 85
Each patient will have ample time and opportunity to ask questions.
Only if the patient voluntarily agrees to sign the informed consent form and has done so, may 
he / she enter the study. Additionally, the investigator will personally sign and date the form. 
The patient will receive a copy of the signed and dated form.
The signed informed consent statement is to remain in the investigator site file or, if locally 
required, in the patient’s note / file of the medical institution.
In the event that informed consent is obtained on the date that baseline study procedures are 
performed, the study record or patient´s clinical record must clearly show that informed 
consent was obtained prior to these procedures.
The informed consent form and any other written information provided to patients will be 
revised whenever important new information becomes available that may be relevant to the 
patient’s consent, or there is an amendment to the protocol that necessitates a change to the 
content of the patient information and / or the written informed consent form. The investigator 
will inform the patient of changes in a timely manner and will ask the patient to confirm 
his / her participation in the study by signing the revised informed consent form. Any revised 
written informed consent form and written information must receive the IEC / IRB’s 
approval / favorable opinion in advance of use.
13.5
Publication policy and use of data
The sponsor has made the information regarding the study protocol publicly available on the 
internet at www.clinicaltrials.gov. 
All data and results and all intellectual property rights in the data and results derived from the 
study will be the property of the sponsor who may utilize them in various ways, such as for 
submission to government regulatory authorities or disclosure to other investigators.
Regarding public disclosure of study results, the sponsor will fulfill its obligations according 
to all applicable laws and regulations. The sponsor is interested in the publication of the 
results of every study it performs. 
The sponsor recognizes the right of the investigator to publish the results upon completion of 
the study. However, the investigator, whilst free to utilize study data derived from his / her 
center for scientific purposes, must obtain written consent of the sponsor on the intended 
publication manuscript before its submission. To this end, the investigator must send a draft 
of the publication manuscript to the sponsor within a time period specified in the contract. 
The sponsor will review the manuscript promptly and will discuss its content with the 
investigator to reach a mutually agreeable final manuscript. 
13.6
Compensation for health damage of patients / insurance
The sponsor maintains clinical trial insurance coverage for this study in accordance with the 
laws and regulations of the country in which the study is performed.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 75 of 85
13.7
Confidentiality
All records identifying the patient will be kept confidential and, to the extent permitted by the 
applicable laws and / or regulations, will not be made publicly available.
Patient names will not be supplied to the sponsor. Only the patient number will be recorded in 
the CRF, and if the patient name appears on any other document (e.g. pathologist report), it 
must be obliterated before a copy of the document is supplied to the sponsor. Study findings 
stored on a computer will be stored in accordance with local data protection laws. As part of 
the informed consent process, the patients will be informed in writing that representatives of 
the sponsor, IEC / IRB, or regulatory authorities may inspect their medical records to verify 
the information collected, and that all personal information made available for inspection will 
be handled in strictest confidence and in accordance with local data protection laws.
If the results of the study are published, the patient’s identity will remain confidential.
The investigator will maintain a list to enable patients to be identified.
14.
Reference list 
1.
Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson 
PA, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart 
failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart 
failure 2008 of the European Society of Cardiology. Developed in collaboration with the 
Heart Failure Association of the ESC (HFA) and endorsed by the European Society of 
Intensive Care Medicine (ESICM) Eur J Heart Fail. 2008;10(10):933-89.
2.
Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Crushman M, et al. Heart 
disease and stroke statistics--2016 update: a report from the American Heart Association. 
Circulation. 2016;133(4):e38-e360.
3.
Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137-46.
4.
McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD, et al. 
Confirmation of a heart failure epidemic: findings from the Resource Utilization Among 
Congestive Heart Failure (REACH) study. Journal of the American College of 
Cardiology. 2002;39(1):60-9.
5.
Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More 'malignant' than 
cancer? Five-year survival following a first admission for heart failure. European journal 
of heart failure. 2001;3(3):315-22.
6.
Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, et 
al. Characteristics, treatments, and outcomes of patients with preserved systolic function 
hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. Journal of the 
American College of Cardiology. 2007;50(8):768-77.
7.
Butler J, Fonarow GC, Zile MR, Lam CS, Roessig L, Schelbert EB, et al. Developing 
therapies for heart failure with preserved ejection fraction: current state and future 
directions. JACC Heart failure. 2014;2(2):97-112.
8.
Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in 
prevalence and outcome of heart failure with preserved ejection fraction. The New 
England journal of medicine. 2006;355(3):251-9.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 76 of 85
9.
Meta-Analysis Global Group In Chronic heart failure (MAGGIC). Eur Heart J 2012; 33: 
1750-7.
10. Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, et al. 
Trends in patients hospitalized with heart failure and preserved left ventricular ejection 
fraction: prevalence, therapies, and outcomes. Circulation. 2012;126(1):65-75.
11. Fitch K, Pelizzari PM, Pyenson B. The High Cost of Heart Failure for the Medicare 
Population: An Actuarial Cost Analysis. New York, NY: Milliman, Inc; February 2015.
12. Ahmed A, Allman RM, Fonarow GC, Love TE, Zannad F, Dell'italia LJ, et al. Incident 
heart failure hospitalization and subsequent mortality in chronic heart failure: a 
propensity-matched study. Journal of cardiac failure. 2008;14(3):211-8.
13. Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW, Committee ASA, et 
al. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure 
hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure 
National Registry (ADHERE). American heart journal. 2007;153(6):1021-8.
14. Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO. Rehospitalization for heart 
failure: problems and perspectives. Journal of the American College of Cardiology. 
2013;61(4):391-403.
15. Kitzman DW, Little WC, Brubaker PH, et al. Pathophysiological characterization of 
isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002; 288: 
2144-50.
16. Bayeva M, Gheorghiade M, Ardehali H. Mitochondria as a therapeutic target in heart 
failure. Journal of the American College of Cardiology. 2013;61(6):599-610.
17. Bayeva M, Sawicki KT, Butler J, Gheorghiade M, Ardehali H. Molecular and cellular 
basis of viable dysfunctional myocardium. Circulation Heart failure. 2014;7(4):680-91.
18. Kraigher-Krainer E, Shah AM, Gupta DK, Santos A, Claggett B, Pieske B, et al. 
Impaired systolic function by strain imaging in heart failure with preserved ejection 
fraction. Journal of the American College of Cardiology. 2014;63(5):447-56.
19. Schelbert EB, Fonarow GC, Bonow RO, Butler J, Gheorghiade M. Therapeutic targets in 
heart failure: refocusing on the myocardial interstitium. Journal of the American College 
of Cardiology. 2014;63(21):2188-98.
20. Senni M, Paulus WJ, Gavazzi A, Fraser AG, Diez J, Solomon SD, et al. New strategies 
for heart failure with preserved ejection fraction: the importance of targeted therapies for 
heart failure phenotypes. European heart journal. 2014;35(40):2797-815.
21. Neubauer S. The failing heart--an engine out of fuel. The New England journal of 
medicine. 2007;356(11):1140-51.
22. van Bilsen M, Smeets PJ, Gilde AJ, van der Vusse GJ. Metabolic remodelling of the 
failing heart: the cardiac burn-out syndrome? Cardiovascular research. 2004;61(2):218-
26.
23. Phan TT, Abozguia K, Nallur Shivu G, Mahadevan G, Ahmed I, Williams L, et al. Heart 
failure with preserved ejection fraction is characterized by dynamic impairment of active 
relaxation and contraction of the left ventricle on exercise and associated with myocardial 
energy deficiency. Journal of the American College of Cardiology. 2009;54(5):402-9.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 77 of 85
24. Kitzman DW, Upadhya B. Heart Failure with Preserved Ejection Fraction: A 
Heterogenous Disorder with Multi-Factorial Pathophysiology. JACC. 2014;63(5):457-
459. 
25. Udelson JE, Stevenson LW. The Future of Heart Failure Diagnosis, Therapy, and 
Management. Circulation. 2016 Jun 21;133(25):2671-86.
26. Ahmed A, Fleg JL, Gheorghiade M. Heart failure with preserved ejection fraction. The 
New England journal of medicine. 2006;355(17):1829-30; author reply 30-1.
27. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, et al. The 
perindopril in elderly people with chronic heart failure (PEP-CHF) study. European heart 
journal. 2006;27(19):2338-45.
28. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood 
glucose control and vascular outcomes in patients with type 2 diabetes. The New England 
journal of medicine. 2008;358(24):2560-72.
29. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone 
for heart failure with preserved ejection fraction. The New England journal of medicine. 
2014;370(15):1383-92.
30. van Veldhuisen DJ, Cohen-Solal A, Bohm M, Anker SD, Babalis D, Roughton M, et al. 
Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved 
left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol 
Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal 
of the American College of Cardiology. 2009;53(23):2150-8.
31. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, et al. Regional 
variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart 
Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131:34-42.
32. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC, Committee ASA, et 
al. Clinical presentation, management, and in-hospital outcomes of patients admitted with 
acute decompensated heart failure with preserved systolic function: a report from the 
Acute Decompensated Heart Failure National Registry (ADHERE) Database. Journal of 
the American College of Cardiology. 2006;47(1):76-84.
33. Bangalore S, Bhatt DL, Steg PG, Weber MA, Boden WE, Hamm CW, et al. beta-
blockers and cardiovascular events in patients with and without myocardial infarction: 
post hoc analysis from the CHARISMA trial. Circulation Cardiovascular quality and 
outcomes. 2014;7(6):872-81.
34. Borlaug BA, Melenovsky V, Russell SD, Kessler K, Pacak K, Becker LC, et al. Impaired 
chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure 
and a preserved ejection fraction. Circulation. 2006;114(20):2138-47.
35. Brubaker PH, Joo KC, Stewart KP, Fray B, Moore B, Kitzman DW. Chronotropic 
incompetence and its contribution to exercise intolerance in older heart failure patients. 
Journal of cardiopulmonary rehabilitation. 2006;26(2):86-9.
36. Mujib M, Patel K, Fonarow GC, Kitzman DW, Zhang Y, Aban IB, et al. Angiotensin-
converting enzyme inhibitors and outcomes in heart failure and preserved ejection 
fraction. The American journal of medicine. 2013;126(5):401-10.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 78 of 85
37. Patel K, Fonarow GC, Ekundayo OJ, Aban IB, Kilgore ML, Love TE, et al. Beta-
blockers in older patients with heart failure and preserved ejection fraction: class, dosage, 
and outcomes. International journal of cardiology. 2014;173(3):393-401.
38. Patel K, Fonarow GC, Kitzman DW, Aban IB, Love TE, Allman RM, et al. Aldosterone 
antagonists and outcomes in real-world older patients with heart failure and preserved 
ejection fraction. JACC Heart failure. 2013;1(1):40-7.
39. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Drazner MH, et al. 2013 
ACCF/AHA guideline for the management of heart failure: a report of the American 
College of Cardiology Foundation/American Heart Association Task Force on Practice 
Guidelines. Journal of the American College of Cardiology. 2013;62(16):e147-239.
40. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC 
Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task 
Force for the diagnosis and treatment of acute and chronic heart failure of the European 
Society of Cardiology (ESC). Developed with the special contribution of the Heart 
Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200.
41. Shah SJ, Kitzman DW, Borlaug BA, et al. Phenotype-Specific Treatment of Heart Failure 
With Preserved Ejection Fraction. Circulation. 2016;134:73-90.
42. Haass M, Kitzman DW, Anand IS, Miller A, Zile MR, Massie BM, et al. Body mass 
index and adverse cardiovascular outcomes in heart failure patients with preserved 
ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection 
Fraction (I-PRESERVE) trial. Circ Heart Fail. 2011;4:324-331.
43. Dhingra A, Garg A, Kaur S, et al. Epidemiology of heart failure with preserved ejection 
fraction. Curr Heart Fail Rep. 2014;11(4):354-65.
44. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, et al. The 
global health and economic burden of hospitalizations for heart failure: lessons learned 
from hospitalized heart failure registries. Journal of the American College of Cardiology. 
2014;63(12):1123-33.
45. Gheorghiade M, Vaduganathan M, Shah SJ. Evaluative framework for phase II studies in 
patients with heart failure and preserved ejection fraction. JACC Heart failure. 
2013;1(2):123-6.
46. Shah SJ, Gheorghiade M. Heart failure with preserved ejection fraction: treat now by 
treating comorbidities. Jama. 2008;300(4):431-3.
47. Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiade M, et al. 
Phenomapping for novel classification of heart failure with preserved ejection fraction. 
Circulation. 2015;131(3):269-79.
48. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. 
Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 
2014;371(11):993-1004.
49. Gheorghiade M, Greene SJ, Filippatos G, Erdmann E, Ferrari R, Levy PD, et al. 
Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, 
controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur J 
Heart Fail. 2012;14(9):1056-66.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 79 of 85
50. Sabbah HN, Gupta RC, Kohli S, Wang M, Rastogi S, Zhang K, et al. Chronic therapy 
with a partial adenosine A1-receptor agonist improves left ventricular function and 
remodeling in dogs with advanced heart failure. Circulation Heart failure. 2013;6(3):563-
71.
51. Sabbah HN, Sharov V, Riddle JM, Kono T, Lesch M, Goldstein S. Mitochondrial 
abnormalities in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol. 
1992;24(11):1333-47.
52. Sharov VG, Goussev A, Lesch M, Goldstein S, Sabbah HN. Abnormal mitochondrial 
function in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol. 
1998;30(9):1757-62.
53. Sharov VG, Todor AV, Silverman N, Goldstein S, Sabbah HN. Abnormal mitochondrial 
respiration in failed human myocardium. J Mol Cell Cardiol. 2000;32(12):2361-7.
54. Sharov VG, Todor A, Khanal S, Imai M, Sabbah HN. Cyclosporine A attenuates 
mitochondrial permeability transition and improves mitochondrial respiratory function in 
cardiomyocytes isolated from dogs with heart failure. J Mol Cell Cardiol. 
2007;42(1):150-8.
55. Neubauer S. The failing heart--an engine out of fuel. N Engl J Med. 2007;356(11):1140-
51.
56. Hasenfuss G, Pieske B. Calcium cycling in congestive heart failure. J Mol Cell Cardiol. 
2002;34(8):951-69.
57. Conraads VM, Van Craenenbroeck EM, De Maeyer C, Van Berendoncks AM, Beckers 
PJ, Vrints CJ. Unraveling new mechanisms of exercise intolerance in chronic heart 
failure: role of exercise training. Heart Fail Rev. 2013;18(1):65-77.
58. Nell PG, Albrecht-Kupper B. The adenosine A1 receptor and its ligands. Prog Med 
Chem. 2009;47:163-201.
59. Hwang SJ, Melenovsky V, Borlaug BA. Implications of coronary artery disease in heart 
failure with preserved ejection fraction. Journal of the American College of Cardiology. 
2014;63(25 Pt A):2817-27.
60. Rusinaru D, Houpe D, Szymanski C, Levy F, Marechaux S, Tribouilloy C. Coronary 
artery disease and 10-year outcome after hospital admission for heart failure with 
preserved and with reduced ejection fraction. European journal of heart failure. 
2014;16(9):967-76.
61. Baxter GF, Hale SL, Miki T, Kloner RA, Cohen MV, Downey JM, et al. Adenosine A1 
agonist at reperfusion trial (AART): results of a three-center, blinded, randomized, 
controlled experimental infarct study. Cardiovascular drugs and therapy / sponsored by 
the International Society of Cardiovascular Pharmacotherapy. 2000;14(6):607-14.
62. Veres G, Radovits T, Otila G, Hirschberg K, Haider H, Krieger N, et al. Efficacy of the 
non-adenosine analogue A1 adenosine receptor agonist (BR-4935) on cardiovascular 
function after cardiopulmonary bypass. The Thoracic and cardiovascular surgeon. 
2010;58(2):86-92.
63. Bott-Flugel L, Bernshausen A, Schneider H, Luppa P, Zimmermann K, Albrecht-Kupper 
B, et al. Selective attenuation of norepinephrine release and stress-induced heart rate 
increase by partial adenosine A1 agonism. PloS one. 2011;6(3):e18048.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 80 of 85
64. Richardt G, Waas W, Kranzhofer R, Mayer E, Schomig A. Adenosine inhibits exocytotic 
release of endogenous noradrenaline in rat heart: a protective mechanism in early 
myocardial ischemia. Circ Res. 1987;61(1):117-23.
65. Cavender MA, Steg PG, Smith SC, Eagle K, Ohman EM, Goto S, et al. Impact of 
Diabetes on Hospitalization for Heart Failure, Cardiovascular Events, and Death: 
Outcomes at 4 Years from the REACH Registry. Circulation. 2015.
66. Fredholm BB, AP IJ, Jacobson KA, Klotz KN, Linden J. International Union of 
Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol 
Rev. 2001;53(4):527-52.
67. Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, et al. 
Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med. 
2010;363(15):1419-28.
68. Teerlink JR, Iragui VJ, Mohr JP, Carson PE, Hauptman PJ, Lovett DH, et al. The safety 
of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure 
and renal impairment: findings from PROTECT. Drug Saf. 2012;35(3):233-44.
69. Joo JD, Kim M, Horst P, Kim J, D'Agati VD, Emala CW, Sr., et al. Acute and delayed 
renal protection against renal ischemia and reperfusion injury with A1 adenosine 
receptors. Am J Physiol Renal Physiol. 2007;293(6):F1847-57.
70. Capurso C, Capurso A. From excess adiposity to insulin resistance: the role of free fatty 
acids. Vascular pharmacology. 2012;57(2-4):91-7.
71. Djousse L, Benkeser D, Arnold A, Kizer JR, Zieman SJ, Lemaitre RN, et al. Plasma free 
fatty acids and risk of heart failure: the Cardiovascular Health Study. Circulation Heart 
failure. 2013;6(5):964-9.
72. Staehr PM, Dhalla AK, Zack J, Wang X, Ho YL, Bingham J, et al. Reduction of free fatty 
acids, safety, and pharmacokinetics of oral GS-9667, an A(1) adenosine receptor partial 
agonist. J Clin Pharmacol. 2013;53(4):385-92.
73. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. Metabolic 
gene expression in fetal and failing human heart. Circulation. 2001;104(24):2923-31.
74. Sack MN, Kelly DP. The energy substrate switch during development of heart failure: 
gene regulatory mechanisms (Review). Int J Mol Med. 1998;1(1):17-24.
75. Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, et al. MicroRNAs in the 
human heart: a clue to fetal gene reprogramming in heart failure. Circulation. 
2007;116(3):258-67.
76. Albrecht-Kupper BE, Leineweber K, Nell PG. Partial adenosine A1 receptor agonists for 
cardiovascular therapies. Purinergic signalling. 2012;8(Suppl 1):91-9.
77. Sabbah HN, Shimoyama H, Kono T, Gupta RC, Sharov VG, Scicli G, et al. Effects of 
long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left 
ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation. 
1994;89(6):2852-9.
78. Mohammed SF, Borlaug BA, McNulty S, Lewis GD, Lin G, Zakeri R, et al. Resting 
ventricular-vascular function and exercise capacity in heart failure with preserved ejection 
fraction: a RELAX trial ancillary study. Circulation Heart failure. 2014;7(4):580-9.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 81 of 85
79. Phan TT, Shivu GN, Abozguia K, Davies C, Nassimizadeh M, Jimenez D, et al. Impaired 
heart rate recovery and chronotropic incompetence in patients with heart failure with 
preserved ejection fraction. Circulation Heart failure. 2010;3(1):29-34.
80. Murray AJ, Anderson RE, Watson GC, Radda GK, Clarke K. Uncoupling proteins in 
human heart. Lancet. 2004;364(9447):1786-8.
81. American Thoracic Society, Committee on Proficiency Standards for Clinical Pulmonary 
Function Laboratories. ATS statement: guidelines for the six-minute walk test. American 
journal of respiratory and critical care medicine. 2002;166(1):111-7.
82. Kelly RP, Ting CT, Yang TM, Liu CP, Maughan WL, Chang MS, et al. Effective arterial 
elastance as index of arterial vascular load in humans. Circulation. 1992;86(2):513-21.
83. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria 
for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston, Mass: Little 
Brown & Co; 1994. p. 253-6.
84. Bretz F, Pinheiro JC, Branson M. Combining multiple comparisons and modeling 
techniques in dose-response studies. Biometrics. 2005;61(3):738-48.
85. Carpenter JR, Kenward MG. Missing data in randomized controlled trials - a practical 
guide. Chapter 6.2008.
86. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using 
standardized serum creatinine values in the modification of diet in renal disease study 
equation for estimating glomerular filtration rate. Annals of internal medicine. 
2006;145(4):247-54.
87. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the 
oesophagus for bleeding oesophageal varices. The British journal of surgery. 
1973;60(8):646-9.
15.
Protocol amendments
Not applicable.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 82 of 85
16.
Appendices
16.1
Calculating glomerular filtration rate
In accordance with established nephrology practice and guidelines, renal function at baseline 
and throughout the study will be assessed by means of the estimated glomerular filtration rate 
(eGFR), calculated using the Modification of Diet in Renal Disease (MDRD) study 
abbreviated formula.
Isotope dilution mass spectroscopy (IDMS)-traceable MDRD Study Equation:
Conventional units (serum creatinine level is measured in mg/dL)
GFR (mL/min/1.73 m2) = 175 x (serum creatinine)-1.154 x (Age)-0.203 x (0.742 if female) x 
(1.212 if African American)
GFR can be estimated using the calculator provided in the following link: 
http://www.kidney.org/professionals/kdoqi/gfr_calculator
For further information on assessing renal function using GFR estimates, see reference (86).
16.2
Calculating the Child-Pugh score
The severity of liver disease (Table 16–1) will determine the Child-Pugh score (Table 16–2).
Table 16–1: Grading of severity of liver disease
Factor
+1
+2
+3
Bilirubin (mg/dL)
< 2
2 – 3
> 3
Albumin (g/dL)
> 3.5
2.8 – 3.5
< 2.8
International Normalized Ratio
< 1.7
1.7 – 2.3
> 2.3
Ascites
None
Mild
Moderate / Severe
Encephalopathy
None
Grade I - II
Grade III – IV
Source: adapted from (87)
Table 16–2: Classification using the added score from Table 16–1
Child-Pugh Class
A
B
C
Points
5 6
7 – 9
10 15
Source: adapted from (87) 

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 83 of 85
16.3
6-minute walking distance (6MWD) test
The 6MWD test must be performed in accordance with the American Thoracic Society 
Guideline (81).
According to the guideline, the 6MWD test should be carried out indoors, along a long, flat, 
straight, enclosed corridor with hard surface that is seldom traveled. The walking course 
should be preferably 30 m in length, but not less than 25 m (longer walking courses should be 
shortened to 30 m). The length of the corridor and turnaround points should be marked.
Patients will be instructed to walk alone, not run, from one end to the other end of the walking 
course, at their own pace, while attempting to cover as much ground as possible in 6 minutes.
During the walk, patients are allowed to stop, lean against the wall and rest, but should 
resume walking as soon as they feel able to do so. The resting time will be included in the 6 
minutes.
A “warm-up” period before the test should not be performed. The patients should sit at rest in 
a chair, located near the starting position, for at least 10 minutes before the test starts.
Investigators should not walk with the patients. Moreover, only standardized phrases for 
encouragement must be used during the test. To allow reproducibility, standardized phrases 
should be used every minute according to the following pattern:

After the first minute, tell the patient the following (in even tones): “You are doing 
well. You have 5 minutes to go.”

When the timer shows 4 minutes remaining, tell the patient the following: “Keep up 
the good work. You have 4 minutes to go.”

When the timer shows 3 minutes remaining, tell the patient the following: “You are 
doing well. You are halfway done.”

When the timer shows 2 minutes remaining, tell the patient the following: “Keep up 
the good work. You have only 2 minutes left.”

When the timer shows only 1 minute remaining, tell the patient: “You are doing well. 
You have only 1 minute to go.”
To reduce the variability of the 6MWD tests, it is of utmost importance that familiarization-
6MWD test, baseline-test and all following tests are performed under the same conditions.

Wheelchair or scooter dependent / supplemental oxygen patients or those on 
continuous oxygen for severe pulmonary disease are excluded from the study.

The use of a cane is allowed in cane dependent patients, but then these patients need to 
use the same cane at every 6MWD test throughout the study. If the need for walking 
aids should arise at the baseline visit, the same walking aids should also be used at 
every subsequent test.

If a supplemental oxygen therapy should be implemented already at baseline, all 
subsequent 6MWD tests have to be performed under the same “baseline” conditions 
(same flow of oxygen, same application route, and same way of carrying the oxygen 
bottle). 

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 84 of 85

Even if a supplemental oxygen therapy is implemented or modified during the trial 
(e.g. increase of oxygen flow), it is not permitted to perform the subsequent 6MWD 
tests under conditions other than the baseline conditions.
However, a change of test conditions should be avoided, if reasonably possible at least after 
baseline, to have the same conditions in all 6MWD tests.
For quality reasons, the inhalation of supplemental oxygen and the use of walking aids during 
the 6MWD tests must be documented in the eCRF.

Clinical Study Protocol
No.  BAY 1067197 / 17582
14 FEB 2017
Version: 1.0
Page: 85 of 85
16.4
Borg CR 10 Scale and test instructions
Use this rating scale to report how strong your perception of exertion is. First look at the 
verbal expressions. Start with them and then the numbers. Of these ten (10) or “Extremely 
strong – Maximal” is a very important intensity level. This is the most intense perception or 
feeling you have ever had.
If your experience or feeling is “Very weak”, you should say “1”, if it is “Moderate”, say “3”. 
Note that “Moderate” is “3” and thus weaker than “Medium”, “Mean” or “Middle”. If the 
experience is “Strong” or “Heavy” (it feels “Difficult”) say “5”. Note that “Strong” is about 
half of “Maximal”. Is your feeling “Very strong”, choose a number from 6 to 8. If your 
perception or feeling is stronger than “10”, “Extremely strong – Maximal” you can use a 
larger number, e.g. 12 (that’s why “Absolute maximum” is marked with a dot “●”).
It is very important that you report what you actually experience or feel, not what you think 
you should report. Be as spontaneous and honest as possible and try to avoid under- or 
overestimating. Look at the verbal descriptors and then choose a number. 
When rating your exertion give a number (in principle any kind of decimal number is 
allowed) that corresponds to how hard and strenuous you perceive the work to be. The 
perception of exertion is mainly felt as strain and fatigue in your muscles and as 
breathlessness or any aches.
  0
“Nothing at all”, means that you don’t feel any exertion whatsoever, no muscle
fatigue, no breathlessness or difficulties breathing.
  0.3
  0.5 “Extremely weak”, “Just noticeable”
  0.7
  1
“Very weak” means a very light exertion. As taking a shorter walk at your own pace.
  1.5
  2
“Weak”, “Light”
  2.5
  3
“Moderate” is somewhat but not especially hard. It feels good and not difficult to go on
  4
  5
“Strong – Heavy”. The work is hard and tiring, but continuing isn't terribly difficult.
The effort and exertion is about half as intense as “Maximal”.
  6
  7
“Very strong” is quite strenuous. You can still go on, but you really have to push
yourself and you are very tired.
  8
  9
10
“Extremely strong – Maximal” is an extremely strenuous level. For most people this is 
the most strenuous exertion they have ever experienced previously in their lives.
11
  
●
Is “Absolute maximum – Highest possible” for example “12” or even more